<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        271-24-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACTEMRA 20 MG/ML Solution for injection/infusion 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOCILIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        587.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CHUGAI PHARMACEUTICAL CO LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CHUGAI PHARMACEUTICAL CO LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ROCHE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AC07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Actemra contains the active substance tocilizumab, which is a protein made from specific immune cells (monoclonal antibody), that blocks the action of a specific protein (cytokine) called interleukin-6. This protein is involved in inflammatory processes of the body, and blocking it can reduce the inflammation in your body. Actemra helps to reduce symptoms such as pain and swelling in your joints and can also improve your performance of daily tasks. Actemra has been shown to slow the damage to the cartilage and bone of the joints caused by the disease and to improve your ability to do normal daily activities.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Actemra is used to treat adults with moderate to severe active rheumatoid arthritis (RA), an autoimmune disease, if previous therapies did not work well enough. Actemra is usually given in combination with methotrexate. However, Actemra can be given alone if your doctor determines that methotrexate is inappropriate.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Actemra can also be used to treat adults who have not had previous methotrexate treatment if they have severe, active and progressive rheumatoid arthritis.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Actemra is used to treat children with sJIA. Actemra is used for children aged 2 years and over who have active systemic juvenile idiopathic arthritis (sJIA), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash. Actemra is used to improve the symptoms of sJIA and can be given in combination with methotrexate or alone.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Actemra is used to treat children with pJIA. Actemra is used for children aged 2 years and over with active polyarticular juvenile idiopathic arthritis (pJIA), an inflammatory disease that causes pain and swelling in one or more joints. Actemra is used to improve the symptoms of pJIA and can be given in combination with methotrexate or alone.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Actemra is used to treat adults and children aged 2 years and over with severe or life-threatening cytokine release syndrome (CRS), a side-effect in patients treated with chimeric antigen receptor (CAR) T-cell therapies used to treat certain types of cancer.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>You are not to be given Actemra</strong></p><p dir="ltr"><strong>∙ if you are allergic to tocilizumab or any of the other ingredients of this medicine (listed in Section 6).</strong></p><p dir="ltr"><strong>∙ if you have an active, severe infection.</strong></p><p dir="ltr"><strong>If any of these applies to you, tell the doctor or nurse giving you the infusion.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Warnings and precautions&nbsp;</strong></p><p dir="ltr"><strong>Talk to your doctor or nurse before you are given Actemra.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you experience allergic reactions such as chest tightness, wheezing, severe dizziness or light-headedness, swelling of the lips or skin rash during or after the infusion, then tell your doctor immediately.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you have any kind of infection, short- or long-term, or if you often get infections. Tell your doctor immediately if you feel unwell. Actemra can reduce your body&rsquo;s ability to respond to infections and may make an existing infection worse or increase the chance of getting a new infection.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you have had tuberculosis, tell your doctor. Your doctor will check for signs and symptoms of tuberculosis before starting Actemra. If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy tell your doctor immediately.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you have had intestinal ulcers or diverticulitis, tell your doctor. Symptoms would include abdominal pain and unexplained changes in bowel habits with a fever.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you have liver disease, tell your doctor. Before you use Actemra, your doctor may do a blood test to measure your liver function.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If any patient has recently been vaccinated (either adult or child), or is planning a vaccination, tell your doctor. All patients, especially children, should be up-to-date with all their vaccinations before they start treatment with Actemra. Certain types of vaccines should not be used while receiving Actemra.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you have cancer, tell your doctor. Your doctor will have to decide if you can still be given Actemra.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you have cardiovascular risk factors such as raised blood pressure and raised cholesterol levels, tell your doctor. These factors need to be monitored while receiving Actemra.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you have moderate to severe kidney function problems, your doctor will monitor you.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ If you have persistent headaches.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Your doctor will perform blood tests before you are given Actemra, and during your treatment, to determine if you have a low white blood cell count, low platelet count or high liver enzymes.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr"><strong>Actemra is not recommended for use in children under 2 years of age.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If a child has a history of macrophage activation syndrome, (activation and uncontrolled proliferation of specific blood cells), tell your doctor. Your doctor will have to decide if they can still be given Actemra.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other medicines and Actemra</strong></p><p dir="ltr"><strong>Tell your doctor if you are taking any other medicines (or your child is, if they are the patient), or have recently taken any. This includes medicines obtained without a prescription.&nbsp; Actemra can affect the way some medicines work, and the dose of these may require adjustment. If you are using medicines containing any of the following active substances, tell your doctor:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ methylprednisolone, dexamethasone, used to reduce inflammation</strong></p><p dir="ltr"><strong>∙ simvastatin or atorvastatin, used to reduce cholesterol levels</strong></p><p dir="ltr"><strong>∙ calcium channel blockers (e.g. amlodipine), used to treat raised blood pressure</strong></p><p dir="ltr"><strong>∙ theophylline, used to treat asthma</strong></p><p dir="ltr"><strong>∙ warfarin or phenprocoumon, used as a blood thinning agents</strong></p><p dir="ltr"><strong>∙ phenytoin, used to treat convulsions</strong></p><p dir="ltr"><strong>∙ ciclosporin, used to suppress your immune system during organ transplants</strong></p><p dir="ltr"><strong>∙ benzodiazepines (e.g. temazepam), used to relieve anxiety.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Due to lack of clinical experience, Actemra is not recommended for use with other biological medicines for the treatment of RA, sJIA or pJIA.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy, breast-feeding and fertility</strong></p><p dir="ltr"><strong>Actemra is not to be used in pregnancy unless clearly necessary. Talk to your doctor if you are pregnant, may be pregnant, or intend to become pregnant.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Women of childbearing potential must use effective contraception during and up to 3&nbsp;months after treatment.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Stop breast-feeding if you are to be given Actemra, and talk to your doctor. Leave a gap of at least 3 months after your last treatment before you start breast-feeding. It is not known whether Actemra is passed into breast milk.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The data available so far does not suggest any effect on fertility from this treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr"><strong>This medicine can cause dizziness. If you feel dizzy, do not drive or use machines.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Actemra contains sodium</strong></p><p dir="ltr"><strong>This medicine contains 26.55&nbsp;mg sodium per maximum dose of 1200&nbsp;mg. Take this into account if you are on a low-sodium diet. However, doses below 1025&nbsp;mg of this medicine contain less than 23&nbsp;mg sodium, so they are virtually sodium free.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>This medicine is subject to restricted medical prescription by your doctor.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Actemra will be given to you as a drip into a vein, by a doctor or a nurse. They will dilute the solution, set up the intravenous infusion and monitor you during and after the treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adult patients with RA</strong></p><p dir="ltr"><strong>The usual dose of Actemra is 8&nbsp;mg per kg of body weight. Depending on your response, your doctor may decrease your dose to 4&nbsp;mg/kg then increase back to 8&nbsp;mg/kg when appropriate.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adults will be given Actemra once every 4 weeks through a drip in the vein (intravenous infusion) over one hour.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children with sJIA (aged 2 and over)</strong></p><p dir="ltr"><strong>The usual dose of Actemra depends on your weight.</strong></p><p dir="ltr"><strong>∙ If you weigh less than 30&nbsp;kg: the dose is 12&nbsp;mg for every kilogram of body weight</strong></p><p dir="ltr"><strong>∙ If you weigh 30&nbsp;kg or more, the dose is 8&nbsp;mg for every kilogram of body weight</strong></p><p dir="ltr"><strong>The dose is calculated based on your body weight at each administration.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children with sJIA will be given Actemra once every 2 weeks through a drip in the vein (intravenous infusion) over one hour.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children with pJIA (aged 2 and over)</strong></p><p dir="ltr"><strong>The usual dose of Actemra depends on your weight.</strong></p><p dir="ltr"><strong>∙ If you weigh less than 30 kg: the dose is 10mg for every kilogram of body weight&nbsp;</strong></p><p dir="ltr"><strong>∙ If you weigh 30 kg or more: the dose is 8 mg for every kilogram of body weight&nbsp;</strong></p><p dir="ltr"><strong>The dose is calculated based on your body weight at each administration.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children with pJIA will be given Actemra once every 4 weeks through a drip in the vein (intravenous infusion) over one hour.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with CRS</strong></p><p dir="ltr"><strong>The usual dose of Actemra is 8 mg for every kg of body weight if you weigh 30&nbsp;kg or more.&nbsp;</strong></p><p dir="ltr"><strong>The dose is 12&nbsp;mg for every kg of body weight if you weigh less than 30&nbsp;kg.&nbsp;</strong></p><p dir="ltr"><strong>Actemra can be given alone or in combination with corticosteroids.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you are given more Actemra than you should</strong></p><p dir="ltr"><strong>Since Actemra is given by a doctor or nurse, it is unlikely that you will be given too much. However, if you are worried, talk to your doctor.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you miss a dose of Actemra</strong></p><p dir="ltr"><strong>Since Actemra is given by a doctor or nurse, it is unlikely that you will miss a dose. However, if you are worried, talk to your doctor or nurse.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you stop being given Actemra</strong></p><p dir="ltr"><strong>You should not stop using Actemra without discussing with your doctor first.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you have any further questions on the use of this medicine, ask your doctor or nurse.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Like all medicines, Actemra can cause side effects, although not everybody gets them. Side effects could occur at least up to 3 months after your last dose of Actemra.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Possible serious side effects: tell a doctor straight away.</strong></p><p dir="ltr"><strong>These are common: they may affect up to 1 in every 10 users</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Signs of serious infections</strong></p><p dir="ltr"><strong>∙ fever and chills&nbsp;</strong></p><p dir="ltr"><strong>∙ mouth or skin blisters&nbsp;</strong></p><p dir="ltr"><strong>∙ stomach ache</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you notice any of these, tell your doctor as soon as possible.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Very common side effects:&nbsp;</strong></p><p dir="ltr"><strong>These may affect more than 1 in every 10 users</strong></p><p dir="ltr"><strong>∙ upper respiratory tract infections with typical symptoms such as cough, blocked nose, runny nose, sore throat and headache</strong></p><p dir="ltr"><strong>∙ high blood fat (cholesterol) levels.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Common side effects:&nbsp;</strong></p><p dir="ltr"><strong>These may affect up to 1 in every 10 users</strong></p><p dir="ltr"><strong>∙ lung infection (pneumonia)</strong></p><p dir="ltr"><strong>∙ shingles (herpes zoster)</strong></p><p dir="ltr"><strong>∙ cold sores (oral herpes simplex), blisters</strong></p><p dir="ltr"><strong>∙ skin infection (cellulitis) sometimes with fever and chills</strong></p><p dir="ltr"><strong>∙ rash and itching, hives</strong></p><p dir="ltr"><strong>∙ allergic (hypersensitivity) reactions</strong></p><p dir="ltr"><strong>∙ eye infection (conjunctivitis)</strong></p><p dir="ltr"><strong>∙ headache, dizziness, high blood pressure</strong></p><p dir="ltr"><strong>∙ mouth ulcers, stomach pain</strong></p><p dir="ltr"><strong>∙ fluid retention (oedema) in the lower legs, weight increase</strong></p><p dir="ltr"><strong>∙ cough, shortness of breath&nbsp;</strong></p><p dir="ltr"><strong>∙ low white blood cell counts shown by blood tests (neutropenia, leucopenia)</strong></p><p dir="ltr"><strong>∙ abnormal liver function tests (increased transaminases)</strong></p><p dir="ltr"><strong>∙ increased bilirubin shown by blood tests</strong></p><p dir="ltr"><strong>∙ low fibrinogen levels in the blood (a protein involved in blood clotting).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Uncommon side effects:&nbsp;</strong></p><p dir="ltr"><strong>These may affect up to 1 in every 100 users</strong></p><p dir="ltr"><strong>∙ diverticulitis (fever, nausea, diarrhoea, constipation, stomach pain)</strong></p><p dir="ltr"><strong>∙ red swollen areas in the mouth</strong></p><p dir="ltr"><strong>∙ high blood fat (triglycerides)</strong></p><p dir="ltr"><strong>∙ stomach ulcer</strong></p><p dir="ltr"><strong>∙ kidney stones&nbsp;</strong></p><p dir="ltr"><strong>∙ underactive thyroid.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Very rare side effects:</strong></p><p dir="ltr"><strong>These may affect up to 1 in every 10,000 users</strong></p><p dir="ltr"><strong>∙ low counts for white blood cells, red blood cells and platelets in blood tests.</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>stevens-johnson syndrome (skin rash, which may lead to severe blistering and peeling of the skin)</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Hepatobiliary disorders: Biliary colic, Biliary Dyskinesia, Cholecystitis, Cholecystitis Acute, Cholecystitis Chronic,Cholelithiasis, Chronic Hepatitis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Function Abnormal,Hepatic Steatosis, Hepatomegaly, Hepatotoxicity, Hyperbilirubinaemia, Liver Disorder, NonAlcoholic Steatohepatitis</strong></p></li></ul><p><br />&nbsp;</p><p dir="ltr"><strong>Reporting of side effects</strong></p><p dir="ltr"><strong>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children with sJIA&nbsp;</strong></p><p dir="ltr"><strong>In general, side effects in sJIA patients were of a similar type to those in adults with RA. Some side effects were seen more often: inflamed nose and throat, diarrhoea, lower white blood cell counts and higher liver enzymes.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children with pJIA&nbsp;</strong></p><p dir="ltr"><strong>In general, side effects in pJIA patients were of a similar type to those in adults with RA. Some side effects were seen more often: inflamed nose and throat, headache, feeling sick (nausea) and lower white blood cell counts.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Keep Actemra out of the sight and reach of children.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Keep the vial in the outer carton in order to protect from light.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Do not use this medicine after the expiry date which is stated on the carton.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>∙ The active substance is tocilizumab.&nbsp;</strong></p><p dir="ltr"><strong>Each 4&nbsp;mL vial contains 80&nbsp;mg tocilizumab (20&nbsp;mg/mL).</strong></p><p dir="ltr"><strong>Each 10&nbsp;mL vial contains 200&nbsp;mg tocilizumab (20&nbsp;mg/mL).&nbsp;</strong></p><p dir="ltr"><strong>Each 20&nbsp;mL vial contains 400&nbsp;mg tocilizumab (20&nbsp;mg/mL).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ The other ingredients are sucrose, polysorbate 80, disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate and water for injections.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Actemra is a concentrate for solution for infusion. The concentrate is a clear to opalescent, colourless to pale yellow liquid.
Actemra is supplied as vials containing 4 mL, 10 mL and 20 mL concentrate for solution for infusion. Pack size of 1 and 4 vials. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124,</strong></p><p dir="ltr"><strong>CH-4070 Basel,</strong></p><p dir="ltr"><strong>Switzerland.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2019


To report any side effect(s):

Saudi Arabia:

The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
Reporting hotline: 19999
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc


 Other GCC States:
Please contact the relevant competent authority.


Council of Arab Health Ministers

This is a Medicament
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
The doctor and the pharmacist are the experts in medicines, their benefits and risks.
Do not by yourself interrupt the period of treatment prescribed for you.
Do not repeat the same prescription without consulting your doctor.
Keep all medicaments out of reach of children.

Council of Arab Health Ministers
Union of Arab Pharmacists



            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl"><strong>يحتوي أكتيمرا على المادة الفعالة توسيليزوماب، وهو بروتين مصنوع من خلايا مناعية محددة (الأجسام المضادة وحيدة النسيلة)، والتي تمنع عمل بروتين معين (السيتوكين) يسمى إنترلوكين 6 هذا البروتين مسبب للعمليات الالتهابية في الجسم، ومنعه يمكن أن يقلل من الالتهابات في الجسم بشكل عام. يعمل أكتيمرا على تقليل بعض الاعراض مثل الألم والتورم في المفاصل كما يعمل على تحسين أدائك للمهام اليومية. لقد ثبت أن أكتيمرا يعمل على تأخير الأضرار التي تلحق بالغضروف وعظام المفاصل التي تسببها الامراض ويمنح القدرة على القيام بالأنشطة اليومية بشكل طبيعي.</strong></p><p>&nbsp;</p><ul><li dir="rtl"><p dir="rtl"><strong>يستخدم أكتيمرا لعلاج البالغين المصابين بالتهاب المفاصل الروماتويدي (RA) متوسط او حاد الحالة، وهو مرض مناعي ذاتي، وذلك في حالة عدم جدوى العلاجات السابقة. وعادة ما يتم إعطاء أكتيمرا بجانب بالميثوتريكسيت. ومع ذلك، يمكن إعطاء دواء الأكتيمرا بمفرده إذا قرر الطبيب أن مزجه بالميثوتريكسيت سيكون غير مناسب.</strong></p></li></ul><p>&nbsp;</p><ul><li dir="rtl"><p dir="rtl"><strong>يمكن أيضًا استخدام دواء الأكتيمرا لعلاج البالغين الذين لم يتلقوا العلاج بالميثوتريكسيت إذا كان لديهم التهاب مفاصل روماتويدي حاد ونشط والمتقدم.</strong></p></li></ul><p>&nbsp;</p><ul><li dir="rtl"><p dir="rtl"><strong>يستخدم أكتيمرا لعلاج الأطفال الذين يعانون من الالتهاب المفصلي اليفعي الجهازي مجهول السبب. كما يستخدم دواء الأكتيمرا لعلاج الأطفال الذين تتراوح أعمارهم بين سنتين وأكثر الذين يعانون من حالة التهاب المفاصل اليفعي الجهازي مجهول السبب (SJIA) النشطة وهو مرض التهابي يسبب الألم والتورم في مفصل واحد أو أكثر وكذلك الحمى والطفح الجلدي. يستخدم دواء الأكتيمرا للتغلب على أعراض الالتهاب المفصلي اليفعي الجهازي مجهول السبب ويمكن إعطاؤه بجانب الميثوتريكسيت أو بمفرده.</strong></p></li></ul><p>&nbsp;</p><ul><li dir="rtl"><p dir="rtl"><strong>يستخدم دواء الأكتيمرا لعلاج الأطفال الذين يعانون من الالتهاب المفصلي مجهول السبب pJIA. يستخدم دواء الأكتيمرا لعلاج الأطفال الذين تتراوح أعمارهم بين سنتين وأكثر الذين يعانون من الالتهاب المفصلي مجهول السبب (pJIA) وهو مرض التهابي يسبب الألم والتورم في مفصل واحد او أكثر. يستخدم دواء الأكتيمرا للتغلب على أعراض الالتهاب المفصلي مجهول السبب pJIA ويمكن إعطاؤه بجانب الميثوتريكسيت أو بمفرده.</strong></p></li></ul><p>&nbsp;</p><ul><li dir="rtl"><p dir="rtl"><strong>يستخدم دواء الأكتيمرا لعلاج البالغين والأطفال الذين تزيد أعمارهم عن عامين والمصابون بمتلازمة إفراز السيتوكين الحادة أو المهدد للحياة، وهو تأثير جانبي يعاني منه المرضى الذين يُعالجون بتلقي مستقبلات المستضد الخيمرية (CAR) والعلاجات المناعية (الخلايا التائية) المستخدمة في علاج أنواع معينة من السرطان.</strong></p></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>لا تستخدم دواء أكتيمرا في الحالات الآتية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من حساسية تجاه مادة التيليزوماب أو أي من المكونات الأخرى لهذا الدواء (المذكورة في الجزئية رقم 6).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من عدوى نشطة وحادة.</strong></p></li></ul><p dir="rtl"><strong>إذا كان أي من هذه الأمور تنطبق عليك، فلابد من أخبار الطبيب أو الممرض الذي يقوم بالحقن.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>التحذيرات والاحتياطات</strong></p><p dir="rtl"><strong>قم باستشارة طبيبك المعالج أو الممرضة قبل البدء باستخدام أكتيمرا.</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من ردود فعل تحسسية مثل ضيق الصدر أو الصفير أو الدوار الشديد أو الضوء الخفيف أو تورم الشفاه أو اللسان أو حكة الوجه أو الجلد أو مرض الشَّرى أو الطفح الجلدي أثناء أو بعد الحقن، فأخبر طبيبك على الفور.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من أي نوع من أنواع العدوى، قصيرة أو طويلة المدى، أو في اغلب الاحيان تعاني من الالتهابات. فأخبر طبيبك على الفور إذا كنت تشعر بتوعك. يمكن أن يقلل دواء أكتيمرا من قدرة جسمك على الاستجابة للعدوى وقد يزيد الإصابة الحالية سوءًا أو يزيد من فرصة الإصابة بعدوى جديدة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت مصابًا بالسل، أخبر طبيبك. وسيقوم طبيبك بتفقد وفحص اثار وأعراض مرض السل قبل بدء اعطاء دواء أكتيمرا. إذا ظهرت أعراض مرض السل (السعال المستمر، فقدان الوزن، الخمول، الحمى الخفيفة) أو أي عدوى أخرى أثناء أو بعد العلاج، فأخبر طبيبك على الفور.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من قرحة معوية أو التهاب الرتج، فأخبر طبيبك. وقد تشمل الأعراض ألام البطن وتغيرات غير مبررة في نظام الأمعاء يصاحبه الحمى.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>&nbsp;إذا كنت تعاني من داء الكبد، فأخبر طبيبك. قبل استخدام دواء أكتيمرا، فقد يقوم طبيبك بإجراء فحص دم لقياس وظائف الكبد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا تم تلقيح أي مريض مؤخرًا (سواء كان بالغًا أو طفلًا)، أو كان يخطط للتلقيح، فأخبر طبيبك. ولابد أن يكون جميع المرضى وخاصة الأطفال قد خضعوا لجميع التطعيمات الخاصة بهم حتى الان وقبل البدء باستخدام دواء أكتيمرا.&nbsp; هناك أنواع معينة من اللقاحات غير مسموح بتلقيها أثناء تلقي دواء أكتيمرا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من السرطان، فأخبر طبيبك. وسيقرر طبيبك ما إذا كان لا يزال من الممكن إعطاؤك دواء أكتيمرا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كانت تعاني من مخاطر الإصابة بالأمراض القلبية الوعائية مثل ارتفاع ضغط الدم وارتفاع مستويات الكوليسترول في الدم، فأخبر طبيبك. يستلزم متابعة هذه العوامل أثناء تلقي دواء أكتيمرا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من مشاكل في وظائف الكلى متوسطة كانت ام حادة، فسوف يقوم طبيبك بمتابعتك.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كان لديك صداع مستمر.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>سيقوم طبيبك بإجراء فحص للدم قبل أن تلقي دواء أكتيمرا، لتحديد ما إذا كنت تعاني من انخفاض في عدد خلايا الدم البيضاء أو انخفاض عدد الصفائح الدموية أو ارتفاع في إنزيمات الكبد.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الأطفال والبالغون</strong></p><p dir="rtl"><strong>لا ينصح تلقي الأطفال دون سن الثانية دواء أكتيمرا.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إذا كان الطفل لديه تاريخ مرضي لمتلازمة تنشيط البلاعم (التنشيط والتكاثر غير المنضبط لخلايا دم محددة)، فأخبر طبيبك. سيتعين على طبيبك أن يقرر ما إذا كان لا يزال من الممكن إعطاؤك دواء أكتيمرا.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>أكتيمرا والأدوية الأخرى&nbsp;</strong></p><p dir="rtl"><strong>أخبر طبيبك إذا كنت تتلقى أي أدوية أخرى (أو إذا كان طفلك يتلقى، إذا كان المريض)، أو إذا كنت قد تلقيت مؤخرًا أي من الادوية الاخرى. وهذا يشمل الأدوية التي تم الحصول عليها دون وصفة طبية. يمكن أن يؤثر دواء أكتيمرا على الطريقة التي تعمل بها بعض الأدوية، وقد يستلزم تغيير الجرعات. إذا كنت تستخدم أدوية تحتوي على أي من المواد الفعالة التالية، فأخبر طبيبك:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>دواء ميثيل بريدنيزولون، ديكساميثازون لتقليل الالتهاب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>دواء سيمفاستاتين أو أتورفاستاتين لخفض مستويات الكوليسترول في الدم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>حاصرات قنوات الكالسيوم (مثل أملوديبين)، لعلاج ارتفاع ضغط الدم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>دواء ثيوفيلين لعلاج الربو</strong></p></li><li dir="rtl"><p dir="rtl"><strong>دواء وارفارين أو فينبروكومون كعامل لتخفيف الدم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>دواء فينيتوين لعلاج التشنجات</strong></p></li><li dir="rtl"><p dir="rtl"><strong>دواء سيكلوسبورين لقمع نظام المناعة لديك أثناء عمليات زرع الأعضاء</strong></p></li><li dir="rtl"><p dir="rtl"><strong>دواء بنزوديازيبينات (مثل تيمازيبام) لتخفيف حدة القلق.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>لا ينصح باستعمال أكتيمرا مع الأدوية الحيوية الأخرى المستخدمة في علاج التهاب المفاصل الروماتويدي أو الالتهاب المفصلي الجهازي مجهول السبب أو الالتهاب اليفعي مجهول السبب، وذلك لعدم كفاية البراهين من التجارب السريرية.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>لا يستخدم أكتيمرا أثناء الحمل إلا للضرورة القصوى. أخبري الطبيب المعالج إذا كنتِ حاملاً أو تخططين للحمل.&nbsp;</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب على النساء اللواتي لديهن قدرة على الإنجاب استخدام موانع فعالة للحمل خلال فترة العلاج وحتى 3 أشهر بعد الانتهاء من العلاج.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>على الأم إيقاف الرضاعة الطبيعية حال استخدام أكتيمرا، مع استشارة الطبيب حول هذا الأمر. والاستمرار بإيقاف الرضاعة الطبيعية بعد آخر جرعة تم تلقيها لفترة لا تقل عن 3 أشهر. حيث أنه غير معلوم إذا كان أكتيمرا ينتقل إلى حليب الأم أو لا.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>البيانات المتاحة حتى الآن لا تشير إلى أي تأثير على الخصوبة قد ينتج من تلقي هذا العلاج.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>القيادة واستخدام الآلات</strong></p><p dir="rtl"><strong>قد يسبب هذا الدواء الشعور بالدوار. تجنب قيادة المركبات أو تشغيل الآلات في حال الشعور بالدوار.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>يحتوي دواء أكتيمرا على الصوديوم</strong></p><p dir="rtl"><strong>يحتوي هذا الدواء على 26.55 مج من الصوديوم لكل جرعة قصوى تبلغ 1200 مج. ضع ذلك في الاعتبار إذا كنت تتبع نظامًا غذائيًا منخفض الصوديوم. ومع ذلك، فإن الجرعات التي تقل عن 1025 مج من هذا الدواء تحتوي على أقل من 23 مج من الصوديوم، لذلك فهي خالية من الصوديوم تقريبًا.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يتم وصف هذا الدواء من قبل طبيبك بشكل محدد.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>سيتم إعطاء دواء أكتيمرا كتنقيط في الوريد، بواسطة طبيب أو ممرضة. سوف يُخفف المحلول ويتم الحقن الوريدي والمتابعة أثناء وبعد تلقي العلاج.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>المرضى البالغين الذين يعانون من التهاب المفاصل الروماتويدي</strong></p><p dir="rtl"><strong>الجرعة المعتادة من دواء أكتيمرا هي 8 مج لكل كيلوغرام من وزن الجسم. وتكون بناءً على الاستجابة للعلاج، قد يخفض طبيبك الجرعة إلى 4 مج / كج ثم يعاود إلى 8 مج / كج عندما يكون ذلك ملائماً.</strong></p><p dir="rtl"><strong>سيتم إعطاء البالغين دواء أكتيمرا مرة واحدة كل 4 أسابيع من خلال الحقن في الوريد (التسريب في الوريد) أكثر من ساعة واحدة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الأطفال الذين يعانون من الالتهاب المفصلي الجهازي مجهول السبب sJIA (الذين تتراوح أعمارهم بين عامين وأكثر)</strong></p><p dir="rtl"><strong>تكون الجرعة المعتادة من دواء أكتيمرا وفقاً للوزن.</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إذا كان وزن الجسم أقل من 30 كجم: فإن الجرعة تكون 12 مج لكل كيلوغرام من وزن الجسم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كان وزن الجسم 30 كجم أو أكثر فإن الجرعة تكون 8 مج لكل كيلوغرام من وزن الجسم</strong></p></li></ul><p dir="rtl"><strong>يتم احتساب الجرعة بناءً على وزن الجسم في كل مرحلة.</strong></p><p dir="rtl"><strong>سيتم تلقي الأطفال الذين يعانون من الالتهاب المفصلي الجهازي مجهول السبب دواء اكتيمرا مرة واحدة كل أسبوعين من خلال الحقن في الوريد (التسريب في الوريد) على مدار ساعة واحدة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الأطفال الذين يعانون من الالتهاب المفصلي مجهول السبب pJIA (الذين تتراوح أعمارهم بين عامين وأكثر)</strong></p><p dir="rtl"><strong>تكون الجرعة المعتادة من دواء أكتيمرا وفقاً للوزن.</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إذا كان وزن الجسم أقل من 30 كجم: فإن الجرعة تكون 10 مج لكل كيلوغرام من وزن الجسم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كان وزن الجسم 30 كجم أو أكثر فإن الجرعة تكون 8 مج لكل كيلوغرام من وزن الجسم</strong></p></li></ul><p dir="rtl"><strong>يتم احتساب الجرعة بناءً على وزن الجسم في كل مرحلة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>سيتم تلقي الأطفال الذين يعانون من الالتهاب المفصلي مجهول السبب دواء اكتيمرا مرة واحدة كل 4 أسابيع من خلال الحقن في الوريد (التسريب في الوريد) على مدار ساعة واحدة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>مرضى متلازمة إفراز السيتوكين&nbsp;</strong></p><p dir="rtl"><strong>تكون الجرعة المعتادة من دواء أكتيمرا هي 8 مج لكل كيلوغرام من وزن الجسم إذا كان وزن الجسم 30 كجم أو أكثر.</strong></p><p dir="rtl"><strong>تكون الجرعة 12 مج لكل كيلوغرام من وزن الجسم إذا كان الوزن أقل من 30 كجم.</strong></p><p dir="rtl"><strong>يمكن إعطاء دواء الأكتيمرا بدون إي اضافات أو بالإضافة الى الستيرويدات القشرية.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>عند تجاوز الجرعة اللازمة من دواء اكتيمرا&nbsp;</strong></p><p dir="rtl"><strong>نظرًا لأن دواء اكتيمرا يتم إعطاؤه بواسطة طبيب أو ممرضة، فمن غير المرجح أن تتلقى جرعة زائدة. ومع ذلك، إذا كنت قلقًا بشأن هذا، فارجع إلى الطبيب المعالج.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إذا فوت جرعة من دواء اكتيمرا</strong></p><p dir="rtl"><strong>نظرًا لأن دواء اكتيمرا يتم إعطاؤه بواسطة طبيب أو ممرضة، فمن غير المرجح أن تفوت الجرعة ومع ذلك، إذا كنت قلقًا بشأن هذا، فارجع إلى الطبيب او الممرضة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إذا توقفت عن تلقي دواء اكتيمرا</strong></p><p dir="rtl"><strong>يجب ألا تتوقف عن تلقي دواء اكتيمرا دون مناقشة ذلك مع الطبيب المعالج أولاً.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاستشر الطبيب او الممرضة.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>فمن المحتمل ان يسبب دواء أكتيمرا بعض الآثار الجانبية مثل باقي الأدوية وعلى الرغم من انه لا يصاب بها الجميع. فمن الممكن أن تحدث تلك الآثار الجانبية بعد آخر جرعة من دواء أكتيمرا ولمدة 3 أشهر على الأقل.</strong></p><p dir="rtl"><strong>الآثار الجانبية الخطيرة المحتملة: أخبر الطبيب على الفور.</strong></p><p dir="rtl"><strong>تعد هذه الاثار الجانبية شائعة: قد تؤثر على مستخدم واحد من بين كل 10 مستخدمين تقريباً</strong></p><p>&nbsp;</p><p dir="rtl"><strong>اثار الالتهابات الخطيرة</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>حمى وقشعريرة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>بثور الفم أو الجلد</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألام المعدة</strong></p></li></ul><p dir="rtl"><strong>إذا تم ملاحظة أيًا من هذه الاعراض فلابد من أخطار الطبيب في أسرع وقت ممكن.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>آثار جانبية شائعة جدا:</strong></p><p dir="rtl"><strong>تعد هذه الاثار الجانبية شائعة كما انها قد تؤثر على مستخدم واحد من بين كل 10 مستخدمين أو أكثر</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>التهابات الجهاز التنفسي العلوي مع بعض الأعراض المألوفة مثل السعال وانسداد الأنف وسيلان الأنف والتهاب الحلق والصداع</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ارتفاع مستوى الدهون في الدم (الكوليسترول).</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>آثار جانبية شائعة جدا:</strong></p><p dir="rtl"><strong>تعد هذه الاثار الجانبية شائعة كما انها قد تؤثر على مستخدم واحد من بين كل 10 مستخدمين تقريباً</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>مرض الرئة (الالتهاب الرئوي)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>داء الحزام الناري (الهربس النطاقي)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>القروح الباردة (الهربس البسيط في الحلق)، البثور</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب الجلد (التهاب النسيج الضام الرخو الخلالي) أحيانًا يصاحبه الحمى والقشعريرة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>طفح جلدي وحكة والشرى</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تفاعلات الحساسية (فرط الحساسية)&nbsp;</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب العين (التهاب الملتحمة / الرمد)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>صداع ودوار وارتفاع ضغط الدم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قرح الفم وآلام المعدة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>احتباس السوائل (الوذمة) في أسفل الساقين وزيادة الوزن</strong></p></li><li dir="rtl"><p dir="rtl"><strong>السعال وضيق التنفس</strong></p></li><li dir="rtl"><p dir="rtl"><strong>نقص عدد خلايا الدم البيضاء التي تظهرها اختبارات الدم (قلة العدلات، قلة الكريات البيض)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اختبارات وظائف الكبد تبدو غير طبيعية (زيادة الترانساميناس / ناقلات الأمين)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>زيادة معدل البيليروبين الذي تظهره اختبارات الدم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض مستويات الفيبرينوجين في الدم (بروتين مسبب تخثر الدم).</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>آثار جانبية غير شائعة:</strong></p><p dir="rtl"><strong>قد تؤثر هذه الاثار على مستخدم واحد من بين كل 100 مستخدم</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>التهاب الرتج (حمى، غثيان، إسهال، إمساك، آلام المعدة)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تورم يصاحبه احمرار في بعض مناطق الحلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ارتفاع نسبة الدهون في الدم (الدهون الثلاثية)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قرحة المعدة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>حصى الكلى</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قصور الغدة الدرقية</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>آثار جانبية نادرة جدا:</strong></p><p dir="rtl"><strong>قد تؤثر هذه الاثار على مستخدم واحد من بين كل 10،000 مستخدم</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>ظهور نقص عدد خلايا الدم البيضاء وخلايا الدم الحمراء والصفائح الدموية في اختبارات الدم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>متلازمة ستيفنز-جونسون (طفح جلدي، مما قد يؤدي إلى ظهور تقرحات شديدة في الجلد وتقشيرها)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الاضطرابات الكبدية الصفراوية: المغص المراري، خلل حركات المرارة، التهاب كيس المرارة، التهاب المرارة الحاد، التهاب المرارة المزمن، تحص صفراوي (حصوات المرارة)، التهاب الكبد المزمن، التهاب الكبد الخلوي، الكيسة كبدية، وظائف كبدية تبدو غير طبيعية، تنكس دهني كبدي، تضخم الكبد، تسمم الكبد، فرط بيليروبين الدم، اضطرابات الكبد، التهاب الكبد الدهني غير الكحولي</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>التبليغ عن الاثار الجانبية</strong></p><p dir="rtl"><strong>إذا كنت تعاني من أي آثار جانبية فتحدث إلى الطبيب أو الصيدلي أو الممرض الخاص بك. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك من خلال الإبلاغ عن الآثار الجانبية المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الأطفال الذين يعانون من الالتهاب المفصلي الجهازي مجهول السبب sJIA</strong></p><p dir="rtl"><strong>&nbsp;تكون الآثار الجانبية للذين يعانوا من الالتهاب المفصلي اليفعي الجهازي عامةً من نفس النوع الذي يعاني منه مرضى التهاب المفاصل الروماتويدي البالغين. في كثير من الأحيان تُلاحظ بعض الآثار الجانبية الاتية: التهاب الأنف والحلق، والإسهال، وانخفاض عدد خلايا الدم البيضاء وارتفاع الإنزيمات الكبدية.&nbsp;</strong></p><p><br /><br />&nbsp;</p><p dir="rtl"><strong>الأطفال الذين يعانون من الالتهاب المفصلي مجهول السبب pJIA</strong></p><p dir="rtl"><strong>&nbsp;تكون الآثار الجانبية للذين يعانوا من الالتهاب المفصلي مجهول السبب عامةً من نفس نوع الاثار الجانبية التي يعاني منها مرضى التهاب المفاصل الروماتويدي البالغين. في كثير من الأحيان تُلاحظ بعض الآثار الجانبية الاتية: التهاب الأنف والحلق، والصداع، والشعور بالمرض (الغثيان) وانخفاض عدد خلايا الدم البيضاء.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يحفظ دواء أكتيمرا بعيدا عن متناول الأطفال.</strong></p><p dir="rtl"><strong>يُخزن في الثلاجة (2 درجة مئوية - 8 درجة مئوية). لا يُسمح بتجميده.</strong></p><p dir="rtl"><strong>تُحفظ الزجاجة في العبوة الكرتونية للحماية من الضوء.</strong></p><p dir="rtl"><strong>لا يستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العبوة الكرتونية.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يحتوي الدواء أكتيمرا على:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يحتوي أكتيمرا على المادة الفعالة توسيليزوماب.&nbsp;</strong></p></li></ul><p dir="rtl"><strong>كل زجاجة 4 مل تحتوي على 80 مج تيليزوماب (20 مج / مل).</strong></p><p dir="rtl"><strong>كل زجاجة 10 مل تحتوي على 200 مج تيليزوماب (20 مج / مل).</strong></p><p dir="rtl"><strong>كل زجاجة 20 مل تحتوي على 400 مج تيليزوماب (20 مج / مل).</strong></p><p dir="rtl">&nbsp;</p><ul><li dir="rtl"><p dir="rtl"><strong>المكونات الأخرى هي السكروز، بوليسوربات 80، فوسفات الصوديوم، فوسفات الصوديوم ثنائي القاعدة، هيدروجين فوسفات الصوديوم ثنائي الهيدرات والماء للحقن.</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>كيف يبدو دواء أكتيمرا وما هي محتويات العبوة</strong></p><p dir="rtl"><strong>دواء أكتيمرا هو محلول مركز للحقن. التركيز صافي لدرجة اللمعان كما انه محلول عديم اللون يميل إلى الاصفرار قليلا.</strong></p><p dir="rtl"><strong>يتم توفير الأكتيمرا في زجاجات تحتوي على 4 مل و10 مل و20 مل محلول مركز للتنقيط. حجم العبوة 1 و4 زجاجات. قد لم يتم تسويق جميع أحجام العبوات.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>مالك رخصة التسويق</strong></p><p dir="rtl"><strong>شركة هوفمان-لا روش،</strong></p><p dir="rtl"><strong>124شارع جرينزاتشر.&nbsp;</strong></p><p dir="rtl"><strong>&nbsp;بازل CH-4070&nbsp;</strong></p><p dir="rtl"><strong>سويسرا</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في تاريخ يناير 2019

للإبلاغ عن الآثار الجانبية 

المملكة العربية السعودية:
-	المركز الوطني للتيقظ والسلامة الدوائية
فاكس: 7662-205-11-966+
للاتصال بالمركز الوطني للتيقظ والسلامة الدوائية، هاتف رقم: 2038222-966+ 
تحويلة: 2317-2356-2340
مركز الاتصال بهيئة الغذاء والدواء: 19999o	
بريد الكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: www.sfda.gov.sa

دول مجلس التعاون الخليجي الأخرى:
-	يرجى التواصل مع الهيئة المعنية ذات الصلة.

مجلس وزراء الصحة العرب
هذا المنتج دوائي
الدواء مستحضر يؤثر على صحتك، واستخدامه بطريقة مخالفة للتعليمات قد يعرضك للخطر. 
اتبع وصف الطبيب لك بدقة، وطريقة الاستخدام المذكورة وتعليمات الصيدلي الذي صرف لك الدواء. 
طبيبك المعالج والصيدلي هما الخبيران بمنافع الدواء وأضراره. 
لا تقطع مدة العلاج المخصصة لك من تلقاء نفسك. 
لا تكرر صرف الدواء بدون استشارة الطبيب. 
احتفظ بجميع الأدوية بعيدا عن متناول الأطفال.

مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب



        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Actemra 20 mg/mL concentrate for solution for infusion.

Black Box Warning: 
WARNING: RISK OF SERIOUS INFECTIONS
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (4.4), Adverse Reactions (4.5)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. 
If a serious infection develops, interrupt ACTEMRA until the infection is controlled. 
Reported infections include: 
Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use.
 
Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
 
Bacterial, viral and other infections due to opportunistic pathogens.
 
The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. 
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions (4.4)]. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL concentrate contains 20 mg tocilizumab*.

Each vial contains 80 mg of tocilizumab* in 4 mL (20 mg/mL).
Each vial contains 200 mg of tocilizumab* in 10 mL (20 mg/mL). 
Each vial contains 400 mg of tocilizumab* in 20 mL (20 mg/mL). 

*humanised IgG1 monoclonal antibody against the human interleukin-6 (IL-6) receptor produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

Excipients with known effects
Each 80 mg vial contains 0.10 mmol (2.21 mg) sodium.
Each 200 mg vial contains 0.20 mmol (4.43 mg) sodium. 
Each 400 mg vial contains 0.39 mmol (8.85 mg) sodium. 

For the full list of excipients, see section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate).

Clear to opalescent, colourless to pale yellow solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Actemra, in combination with methotrexate (MTX), is indicated for:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.&nbsp;</strong></p><p dir="ltr"><strong>∙ the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In these patients, Actemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>Actemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. Actemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Actemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Actemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Actemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of RA, sJIA, pJIA or CRS.&nbsp;</strong></p><p dir="ltr"><strong>All patients treated with Actemra should be given the Patient Alert Card.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Posology</strong></p><p dir="ltr"><strong>RA Patients</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The recommended posology is 8&nbsp;mg/kg body weight, given once every four weeks.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For individuals whose body weight is more than 100&nbsp;kg, doses exceeding 800&nbsp;mg per infusion are not recommended (see section 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Doses above 1.2&nbsp;g have not been evaluated in clinical studies (see section 5.1).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dose adjustments due to laboratory abnormalities (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Liver enzyme abnormalities</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt;&nbsp;1 to 3 x Upper Limit of Normal (ULN)</strong></p></td><td><p dir="ltr"><strong>Modify the dose of the concomitant MTX if appropriate</strong></p><p dir="ltr"><strong>For persistent increases in this range, reduce Actemra dose to 4&nbsp;mg/kg or interrupt Actemra until alanine aminotransferase (ALT) or aspartate aminotransferase (AST) have normalised</strong></p><p dir="ltr"><strong>Restart with 4&nbsp;mg/kg or 8&nbsp;mg/kg, as clinically appropriate</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt;&nbsp;3 to 5 x ULN</strong></p><p dir="ltr"><strong>(confirmed by repeat testing, see section 4.4).</strong></p></td><td><p dir="ltr"><strong>Interrupt Actemra dosing until &lt;&nbsp;3 x ULN and follow recommendations above for &gt;&nbsp;1 to 3 x ULN</strong></p><p dir="ltr"><strong>For persistent increases &gt;&nbsp;3 x ULN, discontinue Actemra</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt;&nbsp;5 x ULN</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>∙ Low absolute neutrophil count (ANC)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In patients not previously treated with Actemra, initiation is not recommended in patients with an absolute neutrophil count (ANC) below 2 x 109/l.</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value<br />(cells x 109/&nbsp;l )</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC &gt;&nbsp;1&nbsp;</strong></p></td><td><p dir="ltr"><strong>Maintain dose</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC 0.5 to 1</strong></p></td><td><p dir="ltr"><strong>Interrupt Actemra dosing</strong></p><p dir="ltr"><strong>When ANC increases &gt;&nbsp;1 x 109/&nbsp;l resume Actemra at 4&nbsp;mg/kg and increase to 8&nbsp;mg/kg as clinically appropriate</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC &lt;&nbsp;0.5</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>∙ Low platelet count</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value<br />(cells x 103/&nbsp;&mu;L)</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>50 to 100</strong></p></td><td><p dir="ltr"><strong>Interrupt Actemra dosing</strong></p><p dir="ltr"><strong>When platelet count &gt;&nbsp;100 x 103/&nbsp;&mu; resume Actemra at 4&nbsp;mg/kg and increase to 8&nbsp;mg/kg as clinically appropriate</strong></p></td></tr><tr><td><p dir="ltr"><strong>&lt;&nbsp;50</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Cytokine Release Syndrome (CRS) (adults and paediatrics)</strong></p><p dir="ltr"><strong>The recommended posology for treatment of CRS given as a 60-minute intravenous infusion is 8&nbsp;mg/kg in patients weighing greater than or equal to 30&nbsp;kg or 12 mg/kg in patients weighing less than 30&nbsp;kg. Actemra can be given alone or in combination with corticosteroids.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If no clinical improvement in the signs and symptoms of CRS occurs after the first dose, up to 3 additional doses of Actemra may be administered. The interval between consecutive doses should be at least 8 hours. Doses exceeding 800 mg per infusion are not recommended in CRS patients.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with severe or life-threatening CRS frequently have cytopenias or elevated ALT or AST due to the underlying malignancy, preceding lymphodepleting chemotherapy or the CRS.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric patients&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>sJIA Patients</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The recommended posology in patients above 2 years of age is 8&nbsp;mg/kg once every 2 weeks in patients weighing greater than or equal to 30&nbsp;kg or 12&nbsp;mg/kg once every 2 weeks in patients weighing less than 30&nbsp;kg. The dose should be calculated based on the patient&rsquo;s body weight at each administration. A change in dose should only be based on a consistent change in the patient&rsquo;s body weight over time.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The safety and efficacy of intravenous Actemra in children below 2 years of age has not been established.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dose interruptions of tocilizumab for the following laboratory abnormalities are recommended in sJIA patients in the tables below. If appropriate, the dose of concomitant MTX and/or other medications should be modified or dosing stopped and tocilizumab dosing interrupted until the clinical situation has been evaluated. As there are many co-morbid conditions that may affect laboratory values in sJIA, the decision to discontinue tocilizumab for a laboratory abnormality should be based upon the medical assessment of the individual patient.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Liver enzyme abnormalities</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt; 1 to 3 x ULN</strong></p></td><td><p dir="ltr"><strong>Modify the dose of the concomitant MTX if appropriate</strong></p><p dir="ltr"><strong>For persistent increases in this range, interrupt Actemra until ALT/AST have normalized.&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt; 3 x ULN to 5x ULN</strong></p></td><td><p dir="ltr"><strong>Modify the dose of the concomitant MTX if appropriate</strong></p><p dir="ltr"><strong>Interrupt Actemra dosing until &lt; 3x ULN and follow recommendations above for &gt;1 to 3x ULN</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt; 5x ULN</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra.&nbsp;</strong></p><p dir="ltr"><strong>The decision to discontinue Actemra in sJIA for a laboratory abnormality should be based on the medical assessment of the individual patient.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>∙ Low absolute neutrophil count (ANC)</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value<br />(cells x 109/&nbsp;l )</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC &gt;&nbsp;1&nbsp;</strong></p></td><td><p dir="ltr"><strong>Maintain dose</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC 0.5 to 1</strong></p></td><td><p dir="ltr"><strong>Interrupt Actemra dosing</strong></p><p dir="ltr"><strong>When ANC increases to &gt;&nbsp;1 x 109/&nbsp;l resume Actemra&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC &lt;&nbsp;0.5</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra</strong></p><p dir="ltr"><strong>The decision to discontinue Actemra in sJIA for a laboratory abnormality should be based on the medical assessment of the individual patient.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>∙ Low platelet count&nbsp;</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value<br />(cells x 103/&mu;l)</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>50 to 100</strong></p></td><td><p dir="ltr"><strong>Modify the dose of the concomitant MTX if appropriate</strong></p><p dir="ltr"><strong>Interrupt Actemra dosing</strong></p><p dir="ltr"><strong>When platelet count is &gt; 100 x 103/&mu;l resume Actemra&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>&lt; 50&nbsp;</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra.&nbsp;</strong></p><p dir="ltr"><strong>The decision to discontinue Actemra in sJIA for a laboratory abnormality should be based on the medical assessment of the individual patient.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Reduction of tocilizumab dose due to laboratory abnormalities has not been studied in sJIA patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Available data suggest that clinical improvement is observed within 6 weeks of initiation of treatment with Actemra. Continued therapy should be carefully reconsidered in a patient exhibiting no improvement within this timeframe.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>pJIA Patients</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The recommended posology in patients above 2 years of age is 8 mg/kg once every 4 weeks in patients weighing greater than or equal to 30 kg or 10 mg/kg once every 4 weeks in patients weighing less than 30 kg. The dose should be calculated based on the patient&rsquo;s body weight at each administration. A change in dose should only be based on a consistent change in the patient&rsquo;s body weight over time.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The safety and efficacy of intravenous Actemra in children below 2 years of age has not been established.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dose interruptions of tocilizumab for the following laboratory abnormalities are recommended in pJIA patients in the tables below. If appropriate, the dose of concomitant MTX and/or other medications should be modified or dosing stopped and tocilizumab dosing interrupted until the clinical situation has been evaluated. As there are many co-morbid conditions that may effect laboratory values in pJIA, the decision to discontinue tocilizumab for a laboratory abnormality should be based upon the medical assessment of the individual patient.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Liver enzyme abnormalities</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt; 1 to 3 x ULN</strong></p></td><td><p dir="ltr"><strong>Modify the dose of the concomitant MTX if appropriate</strong></p><p dir="ltr"><strong>For persistent increases in this range, interrupt Actemra until ALT/AST have normalized.&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt; 3 x ULN to 5x ULN</strong></p></td><td><p dir="ltr"><strong>Modify the dose of the concomitant MTX if appropriate</strong></p><p dir="ltr"><strong>Interrupt Actemra dosing until &lt; 3x ULN and follow recommendations above for &gt;1 to 3x ULN</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt; 5x ULN</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra.&nbsp;</strong></p><p dir="ltr"><strong>The decision to discontinue Actemra in pJIA for a laboratory abnormality should be based on the medical assessment of the individual patient.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>∙ Low absolute neutrophil count (ANC)</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value<br />(cells x 109/&nbsp;l )</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC &gt;&nbsp;1&nbsp;</strong></p></td><td><p dir="ltr"><strong>Maintain dose</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC 0.5 to 1</strong></p></td><td><p dir="ltr"><strong>Interrupt Actemra dosing</strong></p><p dir="ltr"><strong>When ANC increases to &gt;&nbsp;1 x 109/&nbsp;l resume Actemra&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>ANC &lt;&nbsp;0.5</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra</strong></p><p dir="ltr"><strong>The decision to discontinue Actemra in pJIA for a laboratory abnormality should be based on the medical assessment of the individual patient.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>∙ Low platelet count&nbsp;</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Laboratory Value<br />(cells x 103/&mu;l)</strong></p></td><td><p dir="ltr"><strong>Action</strong></p></td></tr><tr><td><p dir="ltr"><strong>50 to 100</strong></p></td><td><p dir="ltr"><strong>Modify the dose of the concomitant MTX if appropriate</strong></p><p dir="ltr"><strong>Interrupt Actemra dosing</strong></p><p dir="ltr"><strong>When platelet count is &gt; 100 x 103/&mu;l resume Actemra&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>&lt; 50&nbsp;</strong></p></td><td><p dir="ltr"><strong>Discontinue Actemra.&nbsp;</strong></p><p dir="ltr"><strong>The decision to discontinue Actemra in pJIA for a laboratory abnormality should be based on the medical assessment of the individual patient.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Reduction of tocilizumab dose due to laboratory abnormalities has not been studied in pJIA patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Available data suggest that clinical improvement is observed within 12 weeks of initiation of treatment with Actemra. Continued therapy should be carefully reconsidered in a patient exhibiting no improvement within this timeframe.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly No dose adjustment is required in patients aged 65 years and older.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment</strong></p><p dir="ltr"><strong>No dose adjustment is required in patients with mild renal impairment. Actemra has not been studied in patients with moderate to severe renal impairment (see section 5.2). Renal function should be monitored closely in these patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic impairment</strong></p><p dir="ltr"><strong>Actemra has not been studied in patients with hepatic impairment. Therefore, no dose recommendations can be made.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Method of administration</strong></p><p>&nbsp;</p><p dir="ltr"><strong>After dilution, Actemra for RA, sJIA, pJIA, and CRS patients should be administered as an intravenous infusion over 1&nbsp;hour.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>RA, sJIA, pJIA and CRS Patients &ge; 30&nbsp;kg</strong></p><p dir="ltr"><strong>Actemra should be diluted to a final volume of 100&nbsp;mL with sterile, non-pyrogenic sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection using aseptic technique.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For instructions on dilution of the medicinal product before administration, see section 6.6.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>sJIA,pJIA and CRS Patients &lt;&nbsp;30 kg</strong></p><p dir="ltr"><strong>Actemra should be diluted to a final volume of 50&nbsp;mL with sterile, non-pyrogenic sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection using aseptic technique.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For instructions on dilution of the medicinal product before administration, see section 6.6.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active, severe infections (see section 4.4).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Traceability</strong></p><p dir="ltr"><strong>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections&nbsp;</strong></p><p dir="ltr"><strong>Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents including Actemra (see section 4.8, undesirable effects). Actemra treatment must not be initiated in patients with active infections (see section 4.3). Administration of Actemra should be interrupted if a patient develops a serious infection until the infection is controlled (see section 4.8). Healthcare professionals should exercise caution when considering the use of Actemra in patients with a history of recurring or chronic infections or with underlying conditions (e.g. diverticulitis, diabetes and interstitial lung disease which may predispose patients to infections.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Vigilance for the timely detection of serious infection is recommended for patients receiving biological treatments for moderate to severe RA, sJIA or pJIA as signs and symptoms of acute inflammation may be lessened, associated with suppression of the acute phase reaction. The effects of tocilizumab on C-reactive protein (CRP), neutrophils and signs and symptoms of infection should be considered when evaluating a patient for a potential infection. Patients (which includes younger children with sJIA or pJIA who may be less able to communicate their symptoms) and parents/guardians of sJIA or pJIA patients, should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tuberculosis</strong></p><p dir="ltr"><strong>As recommended for other biological treatments, RA, sJIA and pJIA patients should be screened for latent tuberculosis (TB) infection prior to starting Actemra therapy. Patients with latent TB should be treated with standard anti-mycobacterial therapy before initiating Actemra. Prescribers are reminded of the risk of false negative tuberculin skin and interferon-gamma TB blood test results, especially in patients who are severely ill or immunocompromised.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients should be instructed to seek medical advice if signs/symptoms (e.g., persistent cough, wasting/weight loss, low grade fever) suggestive of a tuberculosis infection occur during or after therapy with Actemra.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Viral reactivation</strong></p><p dir="ltr"><strong>Viral reactivation (e.g. hepatitis B virus) has been reported with biologic therapies for RA. In clinical studies with tocilizumab, patients who screened positive for hepatitis were excluded.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Complications of diverticulitis</strong></p><p dir="ltr"><strong>Events of diverticular perforations as complications of diverticulitis have been reported uncommonly with Actemra in RA patients (see section 4.8). Actemra should be used with caution in patients with previous history of intestinal ulceration or diverticulitis. Patients presenting with symptoms potentially indicative of complicated diverticulitis, such as abdominal pain, haemorrhage and/or unexplained change in bowel habits with fever should be evaluated promptly for early identification of diverticulitis which can be associated with gastrointestinal perforation.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hypersensitivity reactions</strong></p><p dir="ltr"><strong>Serious hypersensitivity reactions have been reported in association with infusion of Actemra (see section 4.8). Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous infusions even if they have received premedication with steroids and antihistamines. Appropriate treatment should be available for immediate use in the event of an anaphylactic reaction during treatment with Actemra. If an anaphylactic reaction or other serious hypersensitivity / serious infusion related reaction occurs, administration of Actemra should be stopped immediately and Actemra should be permanently discontinued.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Active hepatic disease and hepatic impairment</strong></p><p dir="ltr"><strong>Treatment with Actemra, particularly when administered concomitantly with MTX, may be associated with elevations in hepatic transaminases, therefore, caution should be exercised when considering treatment of patients with active hepatic disease or hepatic impairment (see sections 4.2 and 4.8).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic transaminase elevations</strong></p><p dir="ltr"><strong>In clinical trials, transient or intermittent mild and moderate elevations of hepatic transaminases have been reported commonly with Actemra treatment, without progression to hepatic injury (see section 4.8). An increased frequency of these elevations was observed when potentially hepatotoxic drugs (e.g. MTX) were used in combination with Actemra. When clinically indicated, other liver function tests including bilirubin should be considered.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Caution should be exercised when considering initiation of Actemra treatment in patients with elevated ALT or AST &gt;&nbsp;1.5 x ULN. In patients with baseline ALT or AST &gt;&nbsp;5 x ULN, treatment is not recommended.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In RA patients, ALT and AST levels should be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter. For recommended modifications based on transaminases see section 4.2. For ALT or AST elevations &gt;&nbsp;3&ndash;5 x ULN, confirmed by repeat testing, Actemra treatment should be interrupted.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In sJIA and pJIA patients, ALT and AST levels should be monitored at the time of the second infusion and thereafter according to good clinical practice, see section 4.2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Haematological abnormalities</strong></p><p dir="ltr"><strong>Decreases in neutrophil and platelet counts have occurred following treatment with tocilizumab 8&nbsp;mg/kg in combination with MTX (see section 4.8). There may be an increased risk of neutropenia in patients who have previously been treated with a TNF antagonist.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In patients not previously treated with Actemra, initiation is not recommended in patients with an absolute neutrophil count (ANC) below 2 x 109/l. Caution should be exercised when considering initiation of Actemra treatment in patients with a low platelet count (i.e. platelet count below 100&nbsp;x&nbsp;103/&nbsp;&mu;L). In patients who develop an ANC &lt;&nbsp;0.5 x 109/&nbsp;l or a platelet count &lt;&nbsp;50 x 103/&mu;L, continued treatment is not recommended.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Severe neutropenia may be associated with an increased risk of serious infections, although there has been no clear association between decreases in neutrophils and the occurrence of serious infections in clinical trials with Actemra to date.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In RA patients, neutrophils and platelets should be monitored 4 to 8 weeks after start of therapy and thereafter according to standard clinical practice. For recommended dose modifications based on ANC and platelet counts, see section 4.2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In sJIA and pJIA patients, neutrophils and platelets should be monitored at the time of second infusion and thereafter according to good clinical practice, see section 4.2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Lipid parameters</strong></p><p dir="ltr"><strong>Elevations in lipid parameters including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides were observed in patients treated with tocilizumab (see section&nbsp;4.8). In the majority of patients, there was no increase in atherogenic indices, and elevations in total cholesterol responded to treatment with lipid lowering agents.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In sJIA, pJIA and RA patients, assessment of lipid parameters should be performed 4 to 8 weeks following initiation of Actemra therapy. Patients should be managed according to local clinical guidelines for management of hyperlipidaemia.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Neurological disorders</strong></p><p dir="ltr"><strong>Physicians should be vigilant for symptoms potentially indicative of new-onset central demyelinating disorders. The potential for central demyelination with Actemra is currently unknown.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Malignancy</strong></p><p dir="ltr"><strong>The risk of malignancy is increased in patients with RA. Immunomodulatory medicinal products may increase the risk of malignancy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Vaccinations</strong></p><p dir="ltr"><strong>Live and live attenuated vaccines should not be given concurrently with Actemra as clinical safety has not been established. In a randomized open-label study, adult RA patients treated with Actemra and MTX were able to mount an effective response to both the 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines which was comparable to the response seen in patients on MTX only. It is recommended that all patients, particularly sJIA and pJIA patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Actemra therapy. The interval between live vaccinations and initiation of Actemra therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cardiovascular risk</strong></p><p dir="ltr"><strong>RA patients have an increased risk for cardiovascular disorders and should have risk factors (e.g.&nbsp;hypertension, hyperlipidaemia) managed as part of usual standard of care.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Combination with TNF antagonists</strong></p><p dir="ltr"><strong>There is no experience with the use of Actemra with TNF antagonists or other biological treatments for RA, sJIA or pJIA patients. Actemra is not recommended for use with other biological agents.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Sodium</strong></p><p dir="ltr"><strong>This medicinal product contains 1.17&nbsp;mmol (or 26.55&nbsp;mg) sodium per maximum dose of 1200&nbsp;mg. To be taken into consideration by patients on a controlled sodium diet. Doses below 1025&nbsp;mg of this medicinal product contain less than 1&nbsp;mmol sodium (23&nbsp;mg), i.e. essentially &lsquo;sodium free&rsquo;.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>sJIA Patients</strong></p><p dir="ltr"><strong>Macrophage activation syndrome (MAS) is a serious life-threatening disorder that may develop in sJIA patients. In clinical trials, tocilizumab has not been studied in patients during an episode of active MAS.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Interaction studies have only been performed in adults.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Concomitant administration of a single dose of 10&nbsp;mg/kg tocilizumab with 10-25&nbsp;mg MTX once weekly had no clinically significant effect on MTX exposure.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Population pharmacokinetic analyses did not detect any effect of MTX, non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids on tocilizumab clearance.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The expression of hepatic CYP450 enzymes is suppressed by cytokines, such as IL-6, that stimulate chronic inflammation. Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as tocilizumab, is introduced.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In vitro studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19 and CYP3A4 enzyme expression. Tocilizumab normalises expression of these enzymes.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a study in RA patients, levels of simvastatin (CYP3A4) were decreased by 57% one week following a single dose of tocilizumab, to the level similar to, or slightly higher than, those observed in healthy subjects.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>When starting or stopping therapy with tocilizumab, patients taking medicinal products which are individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 (e.g. . methylprednisolone, dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses may need to be increased to maintain therapeutic effect. Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Women of childbearing potential&nbsp;</strong></p><p dir="ltr"><strong>Women of childbearing potential must use effective contraception during and up to 3 months after treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy&nbsp;</strong></p><p dir="ltr"><strong>There are no adequate data from the use of tocilizumab in pregnant women. A study in animals has shown an increased risk of spontaneous abortion/embryo-foetal death at a high dose (see section 5.3). The potential risk for humans is unknown.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Actemra should not be used during pregnancy unless clearly necessary.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Breast-feeding</strong></p><p dir="ltr"><strong>It is unknown whether tocilizumab is excreted in human breast milk. The excretion of tocilizumab in milk has not been studied in animals. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Actemra should be made taking into account the benefit of breast-feeding to the child and the benefit of Actemra therapy to the woman.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Fertility</strong></p><p dir="ltr"><strong>Available non-clinical data do not suggest an effect on fertility under tocilizumab treatment.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Actemra has minor influence on the ability to drive and use machines (see section 4.8, dizziness).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Summary of the safety profile</strong></p><p dir="ltr"><strong>The most commonly reported ADRs (occurring in &ge;&nbsp;5% of patients treated with tocilizumab monotherapy or in combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The most serious ADRs were serious infections, complications of diverticulitis, and hypersensitivity reactions.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>RA Patients</strong></p><p dir="ltr"><strong>The safety profile of tocilizumab has been studied in 4 placebo-controlled studies (studies II, III, IV and V), 1 MTX-controlled study (study I) and their extension periods (see section 5.1).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The double-blind controlled period was 6 months in four studies (studies I, III, IV and V) and was up to 2 years in one study (study II). In the double-blind controlled studies, 774 patients received tocilizumab 4&nbsp;mg/kg in combination with MTX, 1870 patients received tocilizumab 8&nbsp;mg/kg in combination with MTX or other DMARDs and 288 patients received tocilizumab 8&nbsp;mg/kg monotherapy.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The long-term exposure population includes all patients who received at least one dose of tocilizumab either in the double-blind control period or open label extension phase in the studies. Of the 4009 patients in this population, 3577 received treatment for at least 6 months, 3296 for at least one year, 2806 received treatment for at least 2 years and 1222 for 3 years.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>ADRs from clinical trials and/or post marketing experience with Actemra based on spontaneous case reports, literature cases and cases from non-interventional study programs are listed in Table 1 and are presented by MedDRA system organ class. The corresponding frequency category for each ADR is based on the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&gt;1/10,000 to &lt;1/1,000) or very rare (&lt;1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 1. List of ADRs occurring in patients with RA receiving tocilizumab as monotherapy or in combination with MTX or other DMARDs in the double-blind controlled period or during postmarketing experience&nbsp;</strong></p><table><tbody><tr><td rowspan="2"><p dir="ltr"><strong>MedDRA System Organ Class</strong></p></td><td colspan="3"><p dir="ltr"><strong>Frequency categories with preferred terms</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Infections and infestations</strong></p></td><td><p dir="ltr"><strong>Upper respiratory tract infections</strong></p></td><td><p dir="ltr"><strong>Cellulitis, Pneumonia, Oral herpes simplex, Herpes zoster</strong></p></td><td><p dir="ltr"><strong>Diverticulitis</strong></p></td></tr><tr><td><p dir="ltr"><strong>Gastrointestinal disorders</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Abdominal pain, Mouth ulceration, Gastritis</strong></p></td><td><p dir="ltr"><strong>Stomatitis, Gastric ulcer</strong></p></td></tr><tr><td><p dir="ltr"><strong>Skin and subcutaneous tissue disorders</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Rash, Pruritus, Urticaria</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Nervous system disorders</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Headache, Dizziness</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Investigations</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Hepatic transaminases increased, Weight increased, Total bilirubin increased*</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Vascular disorders</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Hypertension</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Blood and lymphatic system disorders</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Leukopenia, Neutropenia, Hypofibrinogenaemia</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Metabolism and nutrition disorders</strong></p></td><td><p dir="ltr"><strong>Hypercholesterolaemia*</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Hypertriglyceridaemia</strong></p></td></tr><tr><td><p dir="ltr"><strong>General disorders and administration site conditions</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Peripheral oedema, Hypersensitivity reactions</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Eye disorders</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Conjunctivitis</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>Cough, Dyspnoea</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Renal disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td><p dir="ltr"><strong>Nephrolithiasis</strong></p></td></tr><tr><td><p dir="ltr"><strong>Endocrine disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td><p dir="ltr"><strong>Hypothyroidism</strong></p></td></tr></tbody></table><p dir="ltr"><strong>* Includes elevations collected as part of routine laboratory monitoring (see text below)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections&nbsp;</strong></p><p dir="ltr"><strong>In the 6-month controlled studies the rate of all infections reported with tocilizumab 8&nbsp;mg/kg plus DMARD treatment was 127 events per 100 patient years compared to 112 events per 100 patient years in the placebo plus DMARD group. In the long-term exposure population, the overall rate of infections with Actemra was 108 events per 100 patient years exposure.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In 6-month controlled clinical studies, the rate of serious infections with tocilizumab 8&nbsp;mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared to 3.9 events per 100 patient years exposure in the placebo plus DMARD group. In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the tocilizumab group and 1.5 events per 100 patient years of exposure in the MTX group.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the long-term exposure population, the overall rate of serious infections (bacterial, viral and fungal) was 4.7 events per 100 patient years. Reported serious infections, some with fatal outcome, included active tuberculosis, which may present with intrapulmonary or extrapulmonary disease, invasive pulmonary infections, including candidiasis, aspergillosis, coccidioidomycosis and pneumocystis jirovecii, pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis. Cases of opportunistic infections have been reported.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Interstitial Lung Disease</strong></p><p dir="ltr"><strong>Impaired lung function may increase the risk for developing infections. There have been post-marketing reports of interstitial lung disease (including pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gastrointestinal Perforation</strong></p><p dir="ltr"><strong>During the 6-month controlled clinical trials, the overall rate of gastrointestinal perforation was 0.26 events per 100 patient years with tocilizumab therapy. In the long-term exposure population the overall rate of gastrointestinal perforation was 0.28 events per 100 patient years. Reports of gastrointestinal perforation on tocilizumab were primarily reported as complications of diverticulitis including generalised purulent peritonitis, lower gastrointestinal perforation, fistulae and abscess.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infusion reactions&nbsp;</strong></p><p dir="ltr"><strong>In the 6-month controlled trials adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the tocilizumab 8&nbsp;mg/kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group. Events reported during the infusion were primarily episodes of hypertension; events reported within 24 hours of finishing an infusion were headache and skin reactions (rash, urticaria). These events were not treatment limiting.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The rate of anaphylactic reactions (occurring in a total of 8/4,009 patients, 0.2%) was several fold higher with the 4&nbsp;mg/kg dose, compared to the 8&nbsp;mg/kg dose. Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported in a total of 56 out of 4,009&nbsp;patients (1.4%) treated with tocilizumab during the controlled and open label clinical studies. These reactions were generally observed during the second to fifth infusions of tocilizumab (see section 4.4). Fatal anaphylaxis has been reported after marketing authorisation during treatment with tocilizumab (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immunogenicity&nbsp;</strong></p><p dir="ltr"><strong>A total of 2,876 patients have been tested for anti-tocilizumab antibodies in the 6-month controlled clinical trials. Of the 46 patients (1.6%) who developed anti-tocilizumab antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment. Thirty patients (1.1%) developed neutralising antibodies.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Haematological abnormalities:</strong></p><p dir="ltr"><strong>Neutrophils</strong></p><p dir="ltr"><strong>In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/&nbsp;l occurred in 3.4% of patients on tocilizumab 8&nbsp;mg/kg plus DMARDs compared to &lt;&nbsp;0.1% of patients on placebo plus DMARDs. Approximately half of the patients who developed an ANC &lt;&nbsp;1 x 109/&nbsp;l did so within 8 weeks after starting therapy. Decreases below 0.5 x 109/&nbsp;l were reported in 0.3% patients receiving tocilizumab 8&nbsp;mg/kg plus DMARDs. Infections with neutropenia have been reported.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in neutrophil counts remained consistent with what was seen in the 6-month controlled clinical trials.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Platelets</strong></p><p dir="ltr"><strong>In the 6-month controlled trials decreases in platelet counts below 100 x 103/&nbsp;&mu;L occurred in 1.7% of patients on tocilizumab 8&nbsp;mg/kg plus DMARDs compared to &lt;&nbsp;1% on placebo plus DMARDs. These decreases occurred without associated bleeding events.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in platelet counts remained consistent with what was seen in the 6-month controlled clinical trials.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Very rare reports of pancytopenia have occurred in the post marketing setting.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic transaminase elevations</strong></p><p dir="ltr"><strong>During the 6-month controlled trials transient elevations in ALT/AST &gt;&nbsp;3 x ULN were observed in 2.1% of patients on tocilizumab 8&nbsp;mg/kg compared to 4.9% of patients on MTX and in 6.5% of patients who received 8&nbsp;mg/kg tocilizumab plus DMARDs compared to 1.5% of patients on placebo plus DMARDs.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The addition of potentially hepatotoxic drugs (e.g. MTX) to tocilizumab monotherapy resulted in increased frequency of these elevations. Elevations of ALT/AST &gt;&nbsp;5 x ULN were observed in 0.7% of tocilizumab monotherapy patients and 1.4% of tocilizumab plus DMARD patients, the majority of whom were discontinued permanently from tocilizumab treatment. These elevations were not associated with clinically relevant increase in direct bilirubin, nor were they associated with clinical evidence of hepatitis or hepatic impairment. During the double-blind controlled period, the incidence of indirect bilirubin greater than the upper limit of normal, collected as a routine laboratory parameter, is 6.2% in patients treated with 8&nbsp;mg/kg tocilizumab + DMARD. A total of 5.8% of patients experienced an elevation of indirect bilirubin of &gt;&nbsp;1 to 2 x ULN and 0.4% had an elevation of &gt;&nbsp;2 x ULN.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevation in ALT/AST remained consistent with what was seen in the 6-month controlled clinical trials.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Lipid parameters</strong></p><p dir="ltr"><strong>During the 6-month controlled trials, increases of lipid parameters such as total cholesterol, triglycerides, LDL cholesterol, and/or HDL cholesterol have been reported commonly. With routine laboratory monitoring it was seen that approximately 24% of patients receiving Actemra in clinical trials experienced sustained elevations in total cholesterol &ge;&nbsp;6.2&nbsp;mmol/&nbsp;l, with 15% experiencing a sustained increase in LDL to &ge;&nbsp;4.1&nbsp;mmol/&nbsp;l. Elevations in lipid parameters responded to treatment with lipid-lowering agents.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevations in lipid parameters remained consistent with what was seen in the 6-month controlled trials.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Malignancies</strong></p><p dir="ltr"><strong>The clinical data are insufficient to assess the potential incidence of malignancy following exposure to tocilizumab. Long-term safety evaluations are ongoing.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Skin Reactions</strong></p><p dir="ltr"><strong>Very rare reports of Stevens-Johnson Syndrome have occurred in the post marketing setting.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Less Common Clinical Trial Adverse Drug Reactions (&lt;1%)</strong></p><p dir="ltr"><strong>Other infrequent adverse drug reactions occurring at an incidence of less than 1% in rheumatoid arthritis patients treated with ACTEMRA in placebo-controlled trials (6- month control portion for Studies I through V and the 12 month treatment portion of Studies II and VI) was:</strong></p><p dir="ltr"><strong>Hepatobiliary disorders</strong></p><p dir="ltr"><strong>Biliary colic, Biliary Dyskinesia, Cholecystitis, Cholecystitis Acute, Cholecystitis Chronic,</strong></p><p dir="ltr"><strong>Cholelithiasis, Chronic Hepatitis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Function Abnormal, Hepatic Steatosis, Hepatomegaly, Hepatotoxicity, Hyperbilirubinaemia, Liver Disorder, NonAlcoholic Steatohepatitis</strong></p><p>&nbsp;</p><p dir="ltr"><strong>sJIA and pJIA Patients</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The safety profile of tocilizumab in the pediatric population is summarized in the sections on pJIA and sJIA below.&nbsp; In general, the ADRs in pJIA and sJIA patients were similar in type to those seen in RA patients, see section 4.8.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The ADRs in the pJIA and sJIA patients treated with tocilizumab are described below and are presented in the Table 2 by MedDRA system organ class and frequency categories, defined using the following convention:&nbsp; very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10) or uncommon (&ge; 1/1,000 to &lt;1/100)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 2:&nbsp; List of ADRs occurring in clinical trial patients with sJIA or pJIA receiving tocilizumab as monotherapy or in combination with MTX.</strong></p><table><tbody><tr><td><p dir="ltr"><strong>MedDRA SOC</strong></p></td><td><p dir="ltr"><strong>Preferrred term (PT)</strong></p></td><td colspan="3"><p dir="ltr"><strong>Frequency</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Infections and Infestations</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Upper Respiratory Tract Infections&nbsp;</strong></p></td><td><p dir="ltr"><strong>pJIA, sJIA</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Nasopharyngitis</strong></p></td><td><p dir="ltr"><strong>pJIA, sJIA</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="2"><p dir="ltr"><strong>Gastrointestinal Disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Nausea</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>pJIA</strong></p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Diarrhea</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>pJIA, sJIA</strong></p></td><td>&nbsp;</td></tr><tr><td colspan="2"><p dir="ltr"><strong>General disorders and administration site conditions</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Infusion related reactions</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>pJIA1, sJIA2</strong></p></td><td>&nbsp;</td></tr><tr><td colspan="2"><p dir="ltr"><strong>Nervous system disorders</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Headache</strong></p></td><td><p dir="ltr"><strong>pJIA</strong></p></td><td><p dir="ltr"><strong>sJIA</strong></p></td><td>&nbsp;</td></tr><tr><td colspan="2"><p dir="ltr"><strong>Investigations</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Hepatic transaminases increased</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>pJIA</strong></p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Decrease in neutrophil count</strong></p></td><td><p dir="ltr"><strong>sJIA</strong></p></td><td><p dir="ltr"><strong>pJIA</strong></p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Platelet count decreased</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>sJIA</strong></p></td><td><p dir="ltr"><strong>pJIA</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Cholesterol increased</strong></p></td><td>&nbsp;</td><td><p dir="ltr"><strong>sJIA</strong></p></td><td><p dir="ltr"><strong>pJIA</strong></p></td></tr></tbody></table><p dir="ltr"><strong>1.&nbsp; Infusion related reaction events in pJIA patients included but were not limited to headache, nausea and hypotension</strong></p><p dir="ltr"><strong>2.&nbsp; Infusion related reaction events in sJIA patients included but were not limited to rash, urticaria, diarrhoea, epigastric discomfort, arthralgia and headache</strong></p><p>&nbsp;</p><p dir="ltr"><strong>pJIA Patients</strong></p><p dir="ltr"><strong>The safety profile of intravenous Actemra in pJIA has been studied in 188 patients from 2 to 17 years of age. The total patient exposure was 184.4 patient years. The frequency of ADRs in pJIA patients can be found in Table 2. The types of ADRs in pJIA patients were similar to those seen in RA and sJIA patients, see section 4.8. When compared to the adult RA population, events of nasopharyngitis, headache, nausea, and decreased neutrophil count were more frequently reported in the pJIA population. Events of cholesterol increased were less frequently reported in the pJIA population than in the adult RA population.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections</strong></p><p dir="ltr"><strong>The rate of infections in the tocilizumab all exposure population was 163.7 per 100 patient years. The most common events observed were nasopharyngitis and upper respiratory tract infections. The rate of serious infections was numerically higher in patients weighing &lt;30 kg treated with 10&nbsp;mg/kg tocilizumab (12.2 per 100 patient years) compared to patients weighing &ge;30 kg, treated with 8 mg/kg tocilizumab (4.0 per 100 patient years). The incidence of infections leading to dose interruptions was also numerically higher in patients weighing &lt;30 kg treated with 10 mg/kg tocilizumab (21.4%) compared to patients weighing &ge;30 kg, treated with 8 mg/kg tocilizumab (7.6%).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infusion Reactions</strong></p><p dir="ltr"><strong>In pJIA patients, infusion related reactions are defined as all events occurring during or within 24 hours of an infusion. In the tocilizumab all exposure population, 11 patients (5.9%) experienced infusion reactions during the infusion and 38 patients (20.2%) experienced an event within 24 hours of an infusion. The most common events occurring during infusion were headache, nausea and hypotension and within 24 hours of infusion were dizziness and hypotension. In general, the adverse drug reactions observed during or within 24 hours of an infusion were similar in nature to those seen in RA and sJIA patients, see section 4.8.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immunogenicity</strong></p><p dir="ltr"><strong>One patient in the 10 mg/kg &lt; 30kg group developed positive anti-tocilizumab antibodies without developing a hypersensitivity reaction and subsequently withdrew from the study.&nbsp;&nbsp;&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Neutrophils</strong></p><p dir="ltr"><strong>During routine laboratory monitoring in the tocilizumab all exposure population, a decrease in neutrophil count below 1 &times; 109/L occurred in 3.7% of patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Platelets</strong></p><p dir="ltr"><strong>During routine laboratory monitoring in the tocilizumab all exposure population, 1% of patients had a decrease in platelet count to &le; 50 &times; 103/&micro;L without associated bleeding events.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic transaminase elevations</strong></p><p dir="ltr"><strong>During routine laboratory monitoring in the tocilizumab all exposure population, elevation in ALT or AST &ge; 3xULN occurred in 3.7% and &lt;1% of patients, respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Lipid parameters</strong></p><p dir="ltr"><strong>During routine laboratory monitoring in the intravenous Actemra study WA19977 3.4% and 10.4% of patients experienced a post-baseline elevation of their LDL-cholesterol value to &ge;&nbsp;130&nbsp;mg/dL and total cholesterol value to &ge;&nbsp;200&nbsp;mg/dL at any time during the study treatment, respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>sJIA Patients</strong></p><p dir="ltr"><strong>The safety profile of intravenous Actemra in sJIA has been studied in 112 patients from 2 to 17 years of age. In the 12 week double-blind, controlled phase, 75 patients received treatment with tocilizumab (8 mg/kg or 12&nbsp;mg/kg based upon body weight). After 12 weeks or at the time of switching to Actemra, due to disease worsening, patients were treated in the open label extension phase.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In general, the ADRs in sJIA patients were similar in type to those seen in RA patients, see section 4.8. The frequency of ADRs in sJIA patients can be found in Table 2. When compared to the adult RA population, patients with sJIA experienced a higher frequency of nasopharyngitis, decrease in neutrophil counts, hepatic transaminases increased, and diarrhea. Events of cholesterol increased were less frequently reported in the sJIA population than in the adult RA population.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections</strong></p><p dir="ltr"><strong>In the 12 week controlled phase, the rate of all infections in the intravenous Actemra group was 344.7 per 100&nbsp;patient years and 287.0 per 100 patient years in the placebo group. In the open label extension phase (Part II), the overall rate of infections remained similar at 306.6 per 100 patient years.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the 12 week controlled phase, the rate of serious infections in the intravenous Actemra group was 11.5 per 100 patient years. At one year in the open label extension phase the overall rate of serious infections remained stable at 11.3 per 100 patient years. Reported serious infections were similar to those seen in RA patients with the addition of varicella and otitis media.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infusion Reactions</strong></p><p dir="ltr"><strong>Infusion related reactions are defined as all events occurring during or within 24 hours of an infusion. In the 12 week controlled phase, 4% of patients from the tocilizumab group experienced events occurring during infusion. One event (angioedema) was considered serious and life-threatening, and the patient was discontinued from study treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the 12 week controlled phase, 16% of patients in the tocilizumab group and 5.4% of patients in the placebo group experienced an event within 24 hours of infusion. In the tocilizumab group, the events included, but were not limited to rash, urticaria, diarrhea, epigastric discomfort, arthralgia and headache. One of these events, urticaria, was considered serious.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation, were reported in 1 out of 112 patients (&lt;&nbsp;1%) treated with tocilizumab during the controlled and up to and including the open label clinical trial.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immunogenicity</strong></p><p dir="ltr"><strong>All 112 patients were tested for anti-tocilizumab antibodies at baseline. Two patients developed positive anti-tocilizumab antibodies with one of these patients having a hypersensitivity reaction leading to withdrawal. The incidence of anti-tocilizumab antibody formation might be underestimated because of interference of tocilizumab with the assay and higher drug concentration observed in children compared to adults.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Neutrophils</strong></p><p dir="ltr"><strong>During routine laboratory monitoring in the 12 week controlled phase, a decrease in neutrophil counts below 1 x 109/l occurred in 7% of patients in the tocilizumab group, and no decreases in the placebo group.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the open label extension phase, decreases in neutrophil counts below 1 x 109/l, occurred in 15% of the tocilizumab group.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Platelets</strong></p><p dir="ltr"><strong>During routine laboratory monitoring in the 12 week controlled phase, 3% of patients in the placebo group and 1% in the tocilizumab group had a decrease in platelet count to &le; 100 x 103/&micro;l.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the open label extension phase, decreases in platelet counts below 100 x 103/&micro;l, occurred in 3% of patients in the tocilizumab group, without associated bleeding events.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic transaminase elevations</strong></p><p dir="ltr"><strong>During routine laboratory monitoring in the 12 week controlled phase, elevation in ALT or AST &ge; 3 x ULN occurred in 5% and 3% of patients, respectively, in the tocilizumab group, and 0% in the placebo group.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the open label extension phase, elevation in ALT or AST &ge; 3 x ULN occurred in 12% and 4% of patients, respectively, in the tocilizumab group.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immunoglobulin G</strong></p><p dir="ltr"><strong>IgG levels decrease during therapy. A decrease to the lower limit of normal occurred in 15 patients at some point in the study.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Lipid parameters</strong></p><p dir="ltr"><strong>During routine laboratory monitoring in the 12 week controlled phase (study WA18221), 13.4% and 33.3% of patients experienced a post-baseline elevation of their LDL-cholesterol value to &ge; 130 mg/dL and total cholesterol value to &ge; 200 mg/dL at any time during study treatment, respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the open label extension phase (study WA18221), 13.2% and 27.7% of patients experienced a post-baseline elevation of their LDL-cholesterol value to &ge; 130 mg/dL and total cholesterol value to &ge; 200 mg/dL at any time during study treatment, respectively.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>CRS Patients</strong></p><p dir="ltr"><strong>The safety of tocilizumab in CRS has been evaluated in a retrospective analysis of data from clinical trials, where 51 patients were treated with intravenous tocilizumab 8 mg/kg (12 mg/kg for patients less than 30 kg) with or without additional high-dose corticosteroids for severe or life-threatening CAR T-cell-induced CRS. A median of 1 dose of tocilizumab (range, 1-4 doses) was administered.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of suspected adverse reactions</strong></p><p dir="ltr"><strong>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>Saudi Arabia:</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong><img width="550" height="135" src="https://docs.google.com/drawings/u/0/d/stPT5aVb75hcZlGPnyw3zvQ/image?w=550&amp;h=135&amp;rev=1&amp;ac=1&amp;parent=1tIO45-6bUCaSD0bII5X1iyAELzd-G6F8" /></strong></p><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>Other GCC States:</strong></p></li></ul><p dir="ltr"><strong><img width="550" height="37" src="https://docs.google.com/drawings/u/0/d/sRIeWt2L4OGBiCHkf3Rvkzg/image?w=550&amp;h=37&amp;rev=1&amp;ac=1&amp;parent=1tIO45-6bUCaSD0bII5X1iyAELzd-G6F8" /></strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>There are limited data available on overdose with Actemra. One case of accidental overdose was reported in which a patient with multiple myeloma received a single dose of 40&nbsp;mg/kg. No adverse reactions were observed.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No serious adverse reactions were observed in healthy volunteers who received a single dose up to 28&nbsp;mg/kg, although dose limiting neutropenia was observed.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No case of an overdose in the paediatric population has been observed.</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Pharmacotherapeutic group: Immunosuppressants, Interleukin inhibitors; ATC code: L04AC07.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mechanism of action</strong></p><p dir="ltr"><strong>Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). Tocilizumab has been shown to inhibit sIL-6R and mIL-6R-mediated signalling. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, monocytes and fibroblasts. IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>RA Patients</strong></p><p dir="ltr"><strong>Pharmacodynamic effects</strong></p><p dir="ltr"><strong>In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR), serum amyloid A (SAA) and fibrinogen were observed. Consistent with the effect on acute phase reactants, treatment with tocilizumab was associated with reduction in platelet count within the normal range. Increases in haemoglobin levels were observed, through tocilizumab decreasing the IL-6 driven effects on hepcidin production to increase iron availability. In tocilizumab-treated patients, decreases in the levels of CRP to within normal ranges were seen as early as week 2, with decreases maintained while on treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In healthy subjects administered tocilizumab in doses from 2 to 28&nbsp;mg/kg, absolute neutrophil counts decreased to their lowest 3 to 5 days following administration. Thereafter, neutrophils recovered towards baseline in a dose dependent manner. Rheumatoid arthritis patients demonstrated a similar pattern of absolute neutrophil counts following tocilizumab administration (see section 4.8).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical efficacy and safety&nbsp;</strong></p><p dir="ltr"><strong>The efficacy of tocilizumab in alleviating the signs and symptoms of RA was assessed in five randomised, double-blind, multi-centre studies. Studies I-V enrolled patients &ge;&nbsp;18&nbsp;years of age with active RA diagnosed according to the American College of Rheumatology (ACR) criteria and who had at least eight tender and six swollen joints at baseline.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In Study I, tocilizumab was administered intravenously every four weeks as monotherapy. In Studies II, III and V, tocilizumab was administered intravenously every four weeks in combination with MTX vs. placebo and MTX. In Study IV, tocilizumab was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs. The primary endpoint for each of the five studies was the proportion of patients who achieved an ACR 20 response at week 24.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Study I evaluated 673 patients who had not been treated with MTX within six months prior to randomisation and who had not discontinued previous MTX treatment as a result of clinically important toxic effects or lack of response. The majority (67%) of patients were MTX-na&iuml;ve. Doses of 8&nbsp;mg/kg of tocilizumab were given every four weeks as monotherapy. The comparator group was weekly MTX (dose titrated from 7.5&nbsp;mg to a maximum of 20&nbsp;mg weekly over an eight week period).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Study II, a two year study with planned analyses at week 24, week 52 and week 104, evaluated 1,196 patients who had an inadequate clinical response to MTX. Doses of 4 or 8&nbsp;mg/kg of tocilizumab or placebo were given every four weeks as blinded therapy for 52 weeks in combination with stable MTX (10&nbsp;mg to 25&nbsp;mg weekly). After week 52, all patients could receive open-label treatment with tocilizumab 8&nbsp;mg/kg. Of the patients who completed the study who were originally randomised to placebo + MTX, 86% received open-label tocilizumab 8&nbsp;mg/kg in year 2. The primary endpoint at week 24 was the proportion of patients who achieved an ACR 20 response. At week 52 and week 104 the co-primary endpoints were prevention of joint damage and improvement in physical function.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Study III evaluated 623 patients who had an inadequate clinical response to MTX. Doses of 4 or 8&nbsp;mg/kg tocilizumab or placebo were given every four weeks, in combination with stable MTX (10&nbsp;mg to 25&nbsp;mg weekly).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Study IV evaluated 1,220 patients who had an inadequate response to their existing rheumatologic therapy, including one or more DMARDs. Doses of 8&nbsp;mg/kg tocilizumab or placebo were given every four weeks in combination with stable DMARDs.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Study V evaluated 499 patients who had an inadequate clinical response or were intolerant to one or more TNF antagonist therapies. The TNF antagonist therapy was discontinued prior to randomisation. Doses of 4 or 8&nbsp;mg/kg tocilizumab or placebo were given every four weeks in combination with stable MTX (10&nbsp;mg to 25&nbsp;mg weekly).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical response</strong></p><p dir="ltr"><strong>In all studies, patients treated with tocilizumab 8&nbsp;mg/kg had statistically significant higher ACR 20, 50, 70 response rates at 6 months compared to control (Table 3). In study I, superiority of tocilizumab 8&nbsp;mg/kg was demonstrated against the active comparator MTX.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The treatment effect was similar in patients independent of rheumatoid factor status, age, gender, race, number of prior treatments or disease status. Time to onset was rapid (as early as week 2) and the magnitude of response continued to improve with duration of treatment. Continued durable responses were seen for over 3 years in the open label extension studies I-V.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In patients treated with tocilizumab 8&nbsp;mg/kg, significant improvements were noted on all individual components of the ACR response including: tender and swollen joint counts; patients and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients in studies I &ndash; V had a mean Disease Activity Score (DAS28) of 6.5&ndash;6.8 at baseline. Significant reduction in DAS28 from baseline (mean improvement) of 3.1&ndash;3.4 were observed in tocilizumab-treated patients compared to control patients (1.3-2.1). The proportion of patients achieving a DAS28 clinical remission (DAS28 &lt;&nbsp;2.6) was significantly higher in patients receiving tocilizumab (28&ndash;34%) compared to 1&ndash;12% of control patients at 24 weeks. In study II, 65% of patients achieved a DAS28 &lt; 2.6 at week 104 compared to 48% at 52 weeks and 33% of patients at week 24.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a pooled analysis of studies II, III and IV, the proportion of patients achieving an ACR 20, 50 and 70 response was significantly higher (59% vs. 50%, 37% vs. 27%, 18% vs. 11%, respectively) in the tocilizumab 8&nbsp;mg/kg plus DMARD vs. the tocilizumab 4&nbsp;mg/kg plus DMARD group (p&lt;&nbsp;0.03). Similarly the proportion of patients achieving a DAS28 remission (DAS28 &lt;&nbsp;2.6) was significantly higher (31% vs. 16% respectively) in patients receiving tocilizumab 8&nbsp;mg/kg plus DMARD than in patients receiving tocilizumab 4&nbsp;mg/kg plus DMARD (p&lt;&nbsp;0.0001).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 3. ACR responses in placebo-/MTX-/DMARDs-controlled studies (% patients)</strong></p><table><tbody><tr><td>&nbsp;</td><td colspan="2"><p dir="ltr"><strong>Study I</strong></p><p dir="ltr"><strong>AMBITION</strong></p></td><td colspan="2"><p dir="ltr"><strong>Study II</strong></p><p dir="ltr"><strong>LITHE</strong></p></td><td colspan="2"><p dir="ltr"><strong>Study III</strong></p><p dir="ltr"><strong>OPTION</strong></p></td><td colspan="3"><p dir="ltr"><strong>Study IV</strong></p><p dir="ltr"><strong>TOWARD</strong></p></td><td colspan="2"><p dir="ltr"><strong>Study V</strong></p><p dir="ltr"><strong>RADIATE</strong></p></td></tr><tr><td><p dir="ltr"><strong>Week</strong></p></td><td><p dir="ltr"><strong>TCZ</strong></p><p dir="ltr"><strong>8&nbsp;mg/kg</strong></p></td><td><p dir="ltr"><strong>MTX</strong></p></td><td><p dir="ltr"><strong>TCZ</strong></p><p dir="ltr"><strong>8&nbsp;mg/kg +&nbsp;MTX</strong></p></td><td><p dir="ltr"><strong>PBO +&nbsp;MTX</strong></p></td><td><p dir="ltr"><strong>TCZ</strong></p><p dir="ltr"><strong>8&nbsp;mg/kg +&nbsp;MTX</strong></p></td><td><p dir="ltr"><strong>PBO +&nbsp;MTX</strong></p></td><td><p dir="ltr"><strong>TCZ</strong></p><p dir="ltr"><strong>8&nbsp;mg/kg + DMARD</strong></p></td><td colspan="2"><p dir="ltr"><strong>PBO + DMARD</strong></p></td><td><p dir="ltr"><strong>TCZ 8&nbsp;mg/kg +&nbsp;MTX</strong></p></td><td><p dir="ltr"><strong>PBO + MTX</strong><br />&nbsp;</p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>286</strong></p></td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>284</strong></p></td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>398</strong></p></td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>393</strong></p></td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>205</strong></p></td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>204</strong></p></td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>803</strong></p></td><td colspan="2"><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>413</strong></p></td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>170</strong></p></td><td><p dir="ltr"><strong>N =</strong></p><p dir="ltr"><strong>158</strong></p></td></tr><tr><td colspan="12"><p dir="ltr"><strong>ACR 20</strong></p></td></tr><tr><td><p dir="ltr"><strong>24</strong></p></td><td><p dir="ltr"><strong>70%***</strong></p></td><td><p dir="ltr"><strong>52%</strong></p></td><td><p dir="ltr"><strong>56%***</strong></p></td><td><p dir="ltr"><strong>27%</strong></p></td><td><p dir="ltr"><strong>59%***</strong></p></td><td><p dir="ltr"><strong>26%</strong></p></td><td><p dir="ltr"><strong>61%***</strong></p></td><td colspan="2"><p dir="ltr"><strong>24%</strong></p></td><td><p dir="ltr"><strong>50%***</strong></p></td><td><p dir="ltr"><strong>10%</strong></p></td></tr><tr><td><p dir="ltr"><strong>52</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td><p dir="ltr"><strong>56%***</strong></p></td><td><p dir="ltr"><strong>25%</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="12"><p dir="ltr"><strong>ACR 50</strong></p></td></tr><tr><td><p dir="ltr"><strong>24</strong></p></td><td><p dir="ltr"><strong>44%**</strong></p></td><td><p dir="ltr"><strong>33%</strong></p></td><td><p dir="ltr"><strong>32%***</strong></p></td><td><p dir="ltr"><strong>10%</strong></p></td><td><p dir="ltr"><strong>44%***</strong></p></td><td><p dir="ltr"><strong>11%</strong></p></td><td><p dir="ltr"><strong>38%***</strong></p></td><td><p dir="ltr"><strong>9%</strong></p></td><td colspan="2"><p dir="ltr"><strong>29%***</strong></p></td><td><p dir="ltr"><strong>4%</strong></p></td></tr><tr><td><p dir="ltr"><strong>52</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td><p dir="ltr"><strong>36%***</strong></p></td><td><p dir="ltr"><strong>10%</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="12"><p dir="ltr"><strong>ACR 70</strong></p></td></tr><tr><td><p dir="ltr"><strong>24</strong></p></td><td><p dir="ltr"><strong>28%**</strong></p></td><td><p dir="ltr"><strong>15%</strong></p></td><td><p dir="ltr"><strong>13%***</strong></p></td><td><p dir="ltr"><strong>2%</strong></p></td><td><p dir="ltr"><strong>22%***</strong></p></td><td><p dir="ltr"><strong>2%</strong></p></td><td><p dir="ltr"><strong>21%***</strong></p></td><td colspan="2"><p dir="ltr"><strong>3%</strong></p></td><td><p dir="ltr"><strong>12%**</strong></p></td><td><p dir="ltr"><strong>1%</strong></p></td></tr><tr><td><p dir="ltr"><strong>52</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td><p dir="ltr"><strong>20%***</strong></p></td><td><p dir="ltr"><strong>4%</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p dir="ltr"><strong>TCZ - Tocilizumab</strong></p><p dir="ltr"><strong>MTX - Methotrexate</strong></p><p dir="ltr"><strong>PBO - Placebo</strong></p><p dir="ltr"><strong>DMARD - Disease modifying anti-rheumatic drug</strong></p><p dir="ltr"><strong>** - p&lt;&nbsp;0.01, TCZ vs. PBO + MTX/DMARD</strong></p><p dir="ltr"><strong>*** - p&lt;&nbsp;0.0001, TCZ vs. PBO + MTX/DMARD</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Major Clinical Response</strong></p><p dir="ltr"><strong>After 2 years of treatment with tocilizumab plus MTX, 14% of patients achieved a major clinical response (maintenance of an ACR70 response for 24 weeks or more).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Radiographic response</strong></p><p dir="ltr"><strong>In Study II, in patients with an inadequate response to MTX, inhibition of structural joint damage was assessed radiographically and expressed as change in modified Sharp score and its components, the erosion score and joint space narrowing score. Inhibition of joint structural damage was shown with significantly less radiographic progression in patients receiving tocilizumab compared to control (Table 4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the open-label extension of Study II the inhibition of progression of structural joint damage in tocilizumab plus MTX-treated patients was maintained in the second year of treatment. The mean change from baseline at week 104 in total Sharp-Genant score was significantly lower for patients randomised to tocilizumab 8&nbsp;mg/kg plus MTX (p&lt;0.0001) compared with patients who were randomised to placebo plus MTX.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 4. Radiographic mean changes over 52 weeks in Study II</strong></p><table><tbody><tr><td>&nbsp;</td><td><p dir="ltr"><strong>PBO +&nbsp;MTX&nbsp;</strong></p><p dir="ltr"><strong>(+&nbsp;TCZ from week 24)</strong></p><p dir="ltr"><strong>N = 393</strong></p></td><td><p dir="ltr"><strong>TCZ 8&nbsp;mg/kg +&nbsp;MTX</strong><br />&nbsp;</p><p dir="ltr"><strong>N = 398</strong></p></td></tr><tr><td><p dir="ltr"><strong>Total Sharp-Genant score</strong></p></td><td><p dir="ltr"><strong>1.13</strong></p></td><td><p dir="ltr"><strong>0.29*</strong></p></td></tr><tr><td><p dir="ltr"><strong>Erosion score</strong></p></td><td><p dir="ltr"><strong>0.71</strong></p></td><td><p dir="ltr"><strong>0.17*</strong></p></td></tr><tr><td><p dir="ltr"><strong>JSN score</strong></p></td><td><p dir="ltr"><strong>0.42</strong></p></td><td><p dir="ltr"><strong>0.12**</strong></p></td></tr></tbody></table><p dir="ltr"><strong>PBO - Placebo</strong></p><p dir="ltr"><strong>MTX - Methotrexate</strong></p><p dir="ltr"><strong>TCZ - Tocilizumab</strong></p><p dir="ltr"><strong>JSN - Joint space narrowing</strong></p><p dir="ltr"><strong>* - p&le;&nbsp;0.0001, TCZ vs. PBO + MTX</strong></p><p dir="ltr"><strong>** - p&lt;&nbsp;0.005, TCZ vs. PBO + MTX</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Following 1 year of treatment with tocilizumab plus MTX, 85% of patients (n=348) had no progression of structural joint damage, as defined by a change in the Total Sharp Score of zero or less, compared with 67% of placebo plus MTX-treated patients (n=290) (p&nbsp;&le;&nbsp;0.001). This remained consistent following 2 years of treatment (83%; n=353). Ninety three percent (93%; n=271) of patients had no progression between week 52 and week 104.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Health-related and quality of life outcomes</strong></p><p dir="ltr"><strong>Tocilizumab-treated patients reported an improvement in all patient-reported outcomes (Health Assessment Questionnaire Disability Index - HAQ-DI), Short Form-36 and Functional Assessment of Chronic Illness Therapy questionnaires. Statistically significant improvements in HAQ-DI scores were observed in patients treated with Actemra compared with patients treated with DMARDs. During the open-label period of Study II, the improvement in physical function has been maintained for up to 2 years. At Week 52, the mean change in HAQ-DI was -0.58 in the tocilizumab 8&nbsp;mg/kg plus MTX group compared with -0.39 in the placebo + MTX group. The mean change in HAQ-DI was maintained&nbsp;at Week 104 in the tocilizumab 8&nbsp;mg/kg plus MTX group (-0.61).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Haemoglobin levels&nbsp;</strong></p><p dir="ltr"><strong>Statistically significant improvements in haemoglobin levels were observed with tocilizumab compared with DMARDs (p&lt;&nbsp;0.0001) at week 24. Mean haemoglobin levels increased by week 2 and remained within normal range through to week 24.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tocilizumab versus adalimumab in monotherapy</strong></p><p dir="ltr"><strong>Study VI (WA19924), a 24 week double-blinded study that compared tocilizumab monotherapy with adalimumab monotherapy, evaluated 326 patients with RA who were intolerant of MTX or where continued treatment with MTX was considered inappropriate (including MTX inadequate responders). Patients in the tocilizumab arm received an intravenous (IV) infusion of tocilizumab (8&nbsp;mg/kg) every 4 weeks (q4w) and a subcutaneous (SC) placebo injection every 2 weeks (q2w). Patients in the adalimumab arm received an adalimumab SC injection (40&nbsp;mg) q2w plus an IV placebo infusion q4w. A statistically significant superior treatment effect was seen in favour of tocilizumab over adalimumab in control of disease activity from baseline to week 24 for the primary endpoint of change in DAS28 and for all secondary endpoints (Table 5).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 5: Efficacy Results for Study VI (WA19924)</strong></p><table><tbody><tr><td>&nbsp;</td><td><p dir="ltr"><strong>ADA + Placebo (IV)</strong></p><p dir="ltr"><strong>N = 162</strong></p></td><td><p dir="ltr"><strong>TCZ + Placebo (SC)</strong></p><p dir="ltr"><strong>N = 163</strong></p></td><td><p dir="ltr"><strong>p-value(a)</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Primary Endpoint - Mean Change from baseline at Week 24</strong></p></td></tr><tr><td><p dir="ltr"><strong>DAS28 (adjusted mean)&nbsp;</strong></p></td><td><p dir="ltr"><strong>-1.8</strong></p></td><td><p dir="ltr"><strong>-3.3&nbsp;</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Difference in adjusted mean (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>-1.5 (-1.8, -1.1)</strong></p></td><td><p dir="ltr"><strong>&lt;0.0001</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Secondary Endpoints - Percentage of Responders at Week 24 (b)</strong></p></td></tr><tr><td><p dir="ltr"><strong>DAS28 &lt;&nbsp;2.6, n (%)</strong></p></td><td><p dir="ltr"><strong>17 (10.5)</strong></p></td><td><p dir="ltr"><strong>65 (39.9)</strong></p></td><td><p dir="ltr"><strong>&lt;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>DAS28 &le;&nbsp;3.2, n (%)&nbsp;</strong></p></td><td><p dir="ltr"><strong>32 (19.8)&nbsp;</strong></p></td><td><p dir="ltr"><strong>84 (51.5)</strong></p></td><td><p dir="ltr"><strong>&lt;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>ACR20 response, n (%)</strong></p></td><td><p dir="ltr"><strong>80 (49.4)</strong></p></td><td><p dir="ltr"><strong>106 (65.0)</strong></p></td><td><p dir="ltr"><strong>0.0038</strong></p></td></tr><tr><td><p dir="ltr"><strong>ACR50 response, n (%)</strong></p></td><td><p dir="ltr"><strong>45 (27.8)</strong></p></td><td><p dir="ltr"><strong>77 (47.2)</strong></p></td><td><p dir="ltr"><strong>0.0002</strong></p></td></tr><tr><td><p dir="ltr"><strong>ACR70 response, n (%)</strong></p></td><td><p dir="ltr"><strong>29 (17.9)</strong></p></td><td><p dir="ltr"><strong>53 (32.5)</strong></p></td><td><p dir="ltr"><strong>0.0023</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ap value is adjusted for region and duration of RA for all endpoints and additionally baseline value for all continuous&nbsp; endpoints.<br />b Non-responder Imputation used for missing data. Multiplicity controlled using Bonferroni-Holm Procedure</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The overall clinical adverse event profile was similar between tocilizumab and adalimumab. The proportion of patients with serious adverse events was balanced between the treatment groups (tocilizumab 11.7% vs. adalimumab 9.9%). The types of adverse drug reactions in the tocilizumab arm were consistent with the known safety profile of tocilizumab and adverse drug reactions were reported at a similar frequency compared with Table 1. A higher incidence of infections and infestations was reported in the tocilizumab arm (48% vs. 42%), with no difference in the incidence of serious infections (3.1%). Both study treatments induced the same pattern of changes in laboratory safety parameters (decreases in neutrophil and platelet counts, increases in ALT, AST and lipids), however, the magnitude of change and the frequency of marked abnormalities was higher with tocilizumab compared with adalimumab. Four (2.5%) patients in the tocilizumab arm and two (1.2%) patients in the adalimumab arm experienced CTC grade 3 or 4 neutrophil count decreases.&nbsp; Eleven (6.8%) patients in the tocilizumab arm and five (3.1%) patients in the adalimumab arm experienced ALT increases of CTC grade 2 or higher.&nbsp; The mean LDL increase from baseline was 0.64 mmol/L (25&nbsp;mg/dL) for patients in the tocilizumab arm and 0.19&nbsp;mmol/L (7&nbsp;mg/dL) for patients in the adalimumab arm.&nbsp; The safety observed in the tocilizumab arm was consistent with the known safety profile of tocilizumab and no new or unexpected adverse drug reactions were observed (see Table 1).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>MTX na&iuml;ve, Early RA</strong></p><p dir="ltr"><strong>Study VII (WA19926), a 2 year study with the planned primary analysis at week 52 evaluated 1162 MTX-na&iuml;ve adult patients with moderate to severe, active early RA (mean disease duration &le; 6 months). Approximately 20% of patients had received prior treatment with DMARDs other than MTX. This study evaluated the efficacy of IV tocilizumab 4 or 8&nbsp;mg/kg every 4 weeks/MTX combination therapy, IV tocilizumab 8&nbsp;mg/kg monotherapy and MTX monotherapy in reducing the signs and symptoms and rate of progression of joint damage for 104 weeks. The primary endpoint was the proportion of patients achieving DAS28 remission (DAS28 &lt; 2.6) at week 24. A significantly higher proportion of patients in the tocilizumab 8&nbsp;mg/kg + MTX and tocilizumab monotherapy groups met the primary endpoint compared with MTX alone. The tocilizumab 8&nbsp;mg/kg + MTX group also showed statistically significant results across the key secondary endpoints. Numerically greater responses compared with MTX alone were observed in the tocilizumab 8&nbsp;mg/kg monotherapy group in all secondary endpoints, including radiographic endpoints. In this study, ACR/EULAR remission (Boolean and Index) were also analysed as pre-specified exploratory endpoints, with higher responses observed in the tocilizumab groups. The results from study VII are shown in Table 6.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 6: Efficacy Results for Study VII (WA19926) on MTX-na&iuml;ve, early RA patients</strong></p><table><tbody><tr><td colspan="2">&nbsp;</td><td><p dir="ltr"><strong>TCZ 8&nbsp;mg/kg + MTX</strong></p><p dir="ltr"><strong>N=290</strong></p></td><td><p dir="ltr"><strong>TCZ 8&nbsp;mg/kg + placebo</strong></p><p dir="ltr"><strong>N=292</strong></p></td><td><p dir="ltr"><strong>TCZ 4&nbsp;mg/kg +<br />MTX</strong></p><p dir="ltr"><strong>N=288</strong></p></td><td><p dir="ltr"><strong>Placebo + MTX</strong></p><p dir="ltr"><strong>N=287</strong></p></td></tr><tr><td>&nbsp;</td><td colspan="5"><p dir="ltr"><strong>Primary Endpoint</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>DAS28 Remission&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="2"><p dir="ltr"><strong>Week 24&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; n (%)</strong></p></td><td><p dir="ltr"><strong>130 (44.8)***</strong></p></td><td><p dir="ltr"><strong>113 (38.7)***</strong></p></td><td><p dir="ltr"><strong>92 (31.9)</strong></p></td><td><p dir="ltr"><strong>43 (15.0)</strong></p></td></tr><tr><td>&nbsp;</td><td colspan="5"><p dir="ltr"><strong>Key Secondary Endpoints</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>DAS 28 remission</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="2"><p dir="ltr"><strong>Week 52&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; n (%),&nbsp;</strong></p></td><td><p dir="ltr"><strong>142 (49.0)***</strong></p></td><td><p dir="ltr"><strong>115 (39.4)</strong></p></td><td><p dir="ltr"><strong>98 (34.0)</strong></p></td><td><p dir="ltr"><strong>56 (19.5)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>ACR</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="2"><p dir="ltr"><strong>Week 24&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ACR20, n (%)</strong></p></td><td><p dir="ltr"><strong>216 (74.5)*</strong></p></td><td><p dir="ltr"><strong>205 (70.2)</strong></p></td><td><p dir="ltr"><strong>212 (73.6)</strong></p></td><td><p dir="ltr"><strong>187 (65.2)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>ACR50, n (%)</strong></p></td><td><p dir="ltr"><strong>165 (56.9)**</strong></p></td><td><p dir="ltr"><strong>139 (47.6)</strong></p></td><td><p dir="ltr"><strong>138 (47.9)</strong></p></td><td><p dir="ltr"><strong>124 (43.2)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>ACR70, n (%)</strong></p></td><td><p dir="ltr"><strong>112 (38.6)**</strong></p></td><td><p dir="ltr"><strong>88 (30.1)</strong></p></td><td><p dir="ltr"><strong>100 (34.7)</strong></p></td><td><p dir="ltr"><strong>73 (25.4)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Week 52&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ACR20, n (%)</strong></p></td><td><p dir="ltr"><strong>195 (67.2)*</strong></p></td><td><p dir="ltr"><strong>184 (63.0)</strong></p></td><td><p dir="ltr"><strong>181 (62.8)</strong></p></td><td><p dir="ltr"><strong>164 (57.1)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>ACR50, n (%)</strong></p></td><td><p dir="ltr"><strong>162 (55.9)**</strong></p></td><td><p dir="ltr"><strong>144 (49.3)</strong></p></td><td><p dir="ltr"><strong>151 (52.4)</strong></p></td><td><p dir="ltr"><strong>117 (40.8)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>ACR70, n (%)</strong></p></td><td><p dir="ltr"><strong>125 (43.1)**</strong></p></td><td><p dir="ltr"><strong>105 (36.0)</strong></p></td><td><p dir="ltr"><strong>107 (37.2)</strong></p></td><td><p dir="ltr"><strong>83 (28.9)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>HAQ-DI (adjusted mean change from baseline)</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="2"><p dir="ltr"><strong>Week 52</strong></p></td><td><p dir="ltr"><strong>-0.81*</strong></p></td><td><p dir="ltr"><strong>-0.67</strong></p></td><td><p dir="ltr"><strong>-0.75</strong></p></td><td><p dir="ltr"><strong>-0.64</strong></p></td></tr><tr><td>&nbsp;</td><td colspan="5"><p dir="ltr"><strong>Radiographic Endpoints (mean change from baseline)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Week 52&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mTSS</strong></p></td><td><p dir="ltr"><strong>0.08***</strong></p></td><td><p dir="ltr"><strong>0.26</strong></p></td><td><p dir="ltr"><strong>0.42</strong></p></td><td><p dir="ltr"><strong>1.14</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Erosion Score</strong></p></td><td><p dir="ltr"><strong>0.05**</strong></p></td><td><p dir="ltr"><strong>0.15</strong></p></td><td><p dir="ltr"><strong>0.25</strong></p></td><td><p dir="ltr"><strong>0.63</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>JSN</strong></p></td><td><p dir="ltr"><strong>0.03</strong></p></td><td><p dir="ltr"><strong>0.11</strong></p></td><td><p dir="ltr"><strong>0.17</strong></p></td><td><p dir="ltr"><strong>0.51</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Radiographic Non-Progression n (%) (change from baseline in mTSS of &le;0)&nbsp;</strong></p></td><td><p dir="ltr"><strong>226 (83)&Dagger;</strong></p></td><td><p dir="ltr"><strong>226 (82)&Dagger;</strong></p></td><td><p dir="ltr"><strong>211 (79)</strong></p></td><td><p dir="ltr"><strong>194 (73)</strong></p></td></tr><tr><td>&nbsp;</td><td colspan="5"><p dir="ltr"><strong>Exploratory Endpoints</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Week 24: ACR/EULAR Boolean Remission, n (%)</strong></p></td><td><p dir="ltr"><strong>47 (18.4) &Dagger;</strong></p></td><td><p dir="ltr"><strong>38 (14.2)</strong></p></td><td><p dir="ltr"><strong>43 (16.7) &Dagger;</strong></p></td><td><p dir="ltr"><strong>25 (10.0)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>&nbsp; &nbsp; &nbsp; ACR/EULAR Index Remission, n (%)</strong></p></td><td><p dir="ltr"><strong>73 (28.5) &Dagger;</strong></p></td><td><p dir="ltr"><strong>60 (22.6)</strong></p></td><td><p dir="ltr"><strong>58 (22.6)</strong></p></td><td><p dir="ltr"><strong>41 (16.4)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Week 52: ACR/EULAR Boolean Remission, n (%)</strong></p></td><td><p dir="ltr"><strong>59 (25.7) &Dagger;</strong></p></td><td><p dir="ltr"><strong>43 (18.7)</strong></p></td><td><p dir="ltr"><strong>48 (21.1)</strong></p></td><td><p dir="ltr"><strong>34 (15.5)</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ACR/EULAR Index Remission, n (%)</strong></p></td><td><p dir="ltr"><strong>83 (36.1) &Dagger;</strong></p></td><td><p dir="ltr"><strong>69 (30.0)</strong></p></td><td><p dir="ltr"><strong>66 (29.3)</strong></p></td><td><p dir="ltr"><strong>49 (22.4)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>mTSS - modified Total Sharp Score</strong></p><p dir="ltr"><strong>JSN - Joint space narrowing</strong></p><p dir="ltr"><strong>All efficacy comparisons vs Placebo + MTX. ***p&le;0.0001; **p&lt;0.001; *p&lt;0.05;&nbsp;</strong></p><p dir="ltr"><strong>&Dagger;p-value &lt; 0.05 vs. Placebo + MTX, but endpoint was exploratory (not included in the hierarchy of statistical testing and has therefore not been controlled for multiplicity)</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p dir="ltr"><strong>sJIA Patients</strong></p><p dir="ltr"><strong>Clinical efficacy</strong></p><p dir="ltr"><strong>The efficacy of tocilizumab for the treatment of active sJIA was assessed in a 12 week randomised, double blind, placebo-controlled, parallel group, two arm study. Patients included in the trial had a total disease duration of at least 6 months and active disease but were not experiencing an acute flare requiring corticosteroid doses of more than 0.5&nbsp;mg/kg prednisone equivalent. Efficacy for the treatment of macrophage activation syndrome has not been investigated.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients (treated with or without MTX) were randomised (tocilizumab:placebo = 2:1) to one of two treatment groups, 75 patients received tocilizumab infusions every two weeks, either 8&nbsp;mg/kg for patients &ge;&nbsp;30&nbsp;kg or 12&nbsp;mg/kg for patients &lt;&nbsp;30&nbsp;kg and 37 patients were assigned to receiving placebo infusions every two weeks. Corticosteroid tapering was permitted from week six for patients who achieved a JIA ACR70 response. After 12 weeks or at the time of escape, due to disease worsening, patients were treated in the open label phase at weight appropriate dosing.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical response</strong></p><p dir="ltr"><strong>The primary endpoint was the proportion of patients with at least 30% improvement in the JIA ACR core set (JIA ACR30 response) at week 12 and absence of fever (no temperature recording &ge; 37.5&deg;C in the preceding 7 days). Eighty five percent (64/75) of tocilizumab treated patients and 24.3% (9/37) of placebo treated patients achieved this endpoint. These proportions were highly significantly different (p&lt;0.0001).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The percent of patients achieving JIA ACR 30, 50, 70 and 90 responses are shown in Table 7.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 7. JIA ACR response rates at week 12 (% patients)</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Response Rate</strong></p></td><td><p dir="ltr"><strong>Tocilizumab</strong></p><p dir="ltr"><strong>N = 75</strong></p></td><td><p dir="ltr"><strong>Placebo</strong></p><p dir="ltr"><strong>N = 37</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR 30</strong></p></td><td><p dir="ltr"><strong>90.7%1</strong></p></td><td><p dir="ltr"><strong>24.3%</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR 50</strong></p></td><td><p dir="ltr"><strong>85.3%1</strong></p></td><td><p dir="ltr"><strong>10.8%</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR 70</strong></p></td><td><p dir="ltr"><strong>70.7%1</strong></p></td><td><p dir="ltr"><strong>8.1%</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR 90</strong></p></td><td><p dir="ltr"><strong>37.3%1</strong></p></td><td><p dir="ltr"><strong>5.4%</strong></p></td></tr></tbody></table><p dir="ltr"><strong>1p&lt;0.0001, tocilizumab vs. placebo</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Systemic Effects</strong></p><p dir="ltr"><strong>In the tocilizumab treated patients, 85% who had fever due to sJIA at baseline were free of fever (no temperature recording &ge; 37.5&deg;C in the preceding 14 days) at week 12 versus 21% of placebo patients (p&lt;0.0001).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The adjusted mean change in the pain VAS after 12 weeks of tocilizumab treatment was a reduction of 41 points on a scale of 0 - 100 compared to a reduction of 1 for placebo patients (p&lt;0.0001).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Corticosteroid Tapering</strong></p><p dir="ltr"><strong>Patients achieving a JIA ACR70 response were permitted corticosteroid dose reduction. Seventeen (24%) tocilizumab treated patients versus 1 (3%) placebo patient were able to reduce their dose of corticosteroid by at least 20% without experiencing a subsequent JIA ACR30 flare or occurrence of systemic symptoms to week 12 (p=0.028). Reductions in corticosteroids continued, with 44 patients off oral corticosteroids at week 44, while maintaining JIA ACR responses.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Health related and quality of life outcomes</strong></p><p dir="ltr"><strong>At week 12, the proportion of tocilizumab treated patients showing a minimally clinically important improvement in the Childhood Health Assessment Questionnaire &ndash; Disability Index (defined as an individual total score decrease of &ge; 0.13) was significantly higher than in placebo treated patients, 77% versus 19% (p&lt;0.0001).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Laboratory Parameters</strong></p><p dir="ltr"><strong>Fifty out of seventy five (67%) tocilizumab treated patients had a haemoglobin &lt;&nbsp;LLN at baseline. Forty (80%) of these patients had an increase in their haemoglobin to within the normal range at week 12, in comparison to 2 out of 29 (7%) of placebo treated patients with haemoglobin &lt;&nbsp;LLN at baseline (p&lt;0.0001).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>pJIA Patients</strong></p><p dir="ltr"><strong>Clinical efficacy</strong></p><p dir="ltr"><strong>The efficacy of tocilizumab was assessed in a three-part study WA19977 including an open-label extension in children with active pJIA. Part&nbsp;I consisted of a 16-week active tocilizumab treatment lead-in period (n=188) followed by Part&nbsp;II, a 24-week randomized double-blind placebo-controlled withdrawal period (n=163), followed by Part&nbsp;III, a 64-week open-label period. In Part 1, eligible patients &ge; 30 kg received tocilizumab at 8 mg/kg IV every 4 weeks for 4 doses. Patients &lt; 30 kg were randomized 1:1 to receive either tocilizumab 8 mg/kg or 10 mg/kg IV every 4 weeks for 4 doses. Patients who completed Part&nbsp;I of the study and achieved at least a JIA ACR30 response at week 16 compared to baseline were eligible to enter the blinded withdrawal period (Part&nbsp;II) of the study. In Part&nbsp;II, patients were randomized to tocilizumab (same dose received in Part I) or placebo in a 1:1 ratio, stratified by concurrent MTX use and concurrent corticosteroid use. Each patient continued in Part II of the study until Week 40 or until the patient satisfied JIA ACR30 flare criteria (relative to Week 16) and qualified for escape to tocilizumab therapy (same dose received in Part I).&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical response</strong></p><p dir="ltr"><strong>The primary endpoint was the proportion of patients with a JIA ACR30 flare at week 40 relative to week 16. Forty eight percent (48.1%, 39/81) of the patients treated with placebo flared compared with 25.6% (21/82) of tocilizumab treated patients. These proportions were statistically significantly different (p=0.0024).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>At the conclusion of Part I, JIA ACR 30/50/70/90 responses were 89.4%, 83.0%, 62.2%, and 26.1%, respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>During the withdrawal phase (Part II), the percentage of patients achieving JIA ACR 30, 50, and 70 responses at Week 40 relative to baseline are shown in Table 8. In this statistical analysis, patients who flared (and escaped to TCZ) during Part II or who withdrew, were classified as non-responders.&nbsp; An additional analyses of JIA ACR responses, considering observed data at Week 40, regardless of flare status, showed that by Week 40, 95.1% of patients who had received continuous TCZ therapy, had achieved JIA ACR30 or higher.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table&nbsp;8.&nbsp; JIA ACR Response Rates at Week 40 Relative to baseline (Percentage of Patients)</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Response Rate</strong></p></td><td><p dir="ltr"><strong>Tocilizumab</strong></p><p dir="ltr"><strong>N=82</strong></p></td><td><p dir="ltr"><strong>Placebo</strong></p><p dir="ltr"><strong>N=81</strong></p></td></tr><tr><td><p dir="ltr"><strong>ACR 30</strong></p></td><td><p dir="ltr"><strong>74.4%*</strong></p></td><td><p dir="ltr"><strong>54.3%*</strong></p></td></tr><tr><td><p dir="ltr"><strong>ACR 50</strong></p></td><td><p dir="ltr"><strong>73.2%*</strong></p></td><td><p dir="ltr"><strong>51.9%*</strong></p></td></tr><tr><td><p dir="ltr"><strong>ACR 70</strong></p></td><td><p dir="ltr"><strong>64.6%*</strong></p></td><td><p dir="ltr"><strong>42.0%*</strong></p></td></tr></tbody></table><p dir="ltr"><strong>* p&lt;0.01, tocilizumab vs. placebo</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The number of active joints was significantly reduced compared to baseline in patients receiving tocilizumab compared to placebo (adjusted mean changes of -14.3 vs -11.4, p=0.0435). The physician&rsquo;s global assessment of disease activity, as measured on a 0-100 mm scale, showed a greater reduction in disease activity for tocilizumab compared to placebo (adjusted mean changes of -45.2 mm vs -35.2 mm, p=0.0031).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The adjusted mean change in the pain VAS after 40 weeks of tocilizumab treatment was 32.4&nbsp;mm on a 0-100&nbsp;mm scale compared to a reduction of 22.3 mm for placebo patients (highly statistically significant; p=0.0076).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The ACR response rates were numerically lower for patients with prior biologic treatment as shown in Table 9 below.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 9. Number and Proportion of Patients with a JIA ACR30 Flare and Proportion of Patients with JIA ACR30/50/70/90 Responses at Week 40, by Previous Biologic Use (ITT Population - Study Part II)</strong></p><p>&nbsp;</p><table><tbody><tr><td>&nbsp;</td><td colspan="2"><p dir="ltr"><strong>Placebo</strong></p></td><td colspan="2"><p dir="ltr"><strong>All TCZ</strong></p></td></tr><tr><td><p dir="ltr"><strong>Biologic Use</strong></p></td><td><p dir="ltr"><strong>Yes (N = 23)</strong></p></td><td><p dir="ltr"><strong>No (N = 58)</strong></p></td><td><p dir="ltr"><strong>Yes (N = 27)</strong></p></td><td><p dir="ltr"><strong>No (N = 55)</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR30 Flare</strong></p></td><td><p dir="ltr"><strong>18 (78.3)</strong></p></td><td><p dir="ltr"><strong>21 (36.2)</strong></p></td><td><p dir="ltr"><strong>12 (44.4)</strong></p></td><td><p dir="ltr"><strong>9 (16.4)</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR30 Response</strong></p></td><td><p dir="ltr"><strong>6 (26.1)</strong></p></td><td><p dir="ltr"><strong>38 (65.5)</strong></p></td><td><p dir="ltr"><strong>15 (55.6)</strong></p></td><td><p dir="ltr"><strong>46 (83.6)</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR50 Response</strong></p></td><td><p dir="ltr"><strong>5 (21.7)</strong></p></td><td><p dir="ltr"><strong>37 (63.8)</strong></p></td><td><p dir="ltr"><strong>14 (51.9)</strong></p></td><td><p dir="ltr"><strong>46 (83.6)</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR70 Response</strong></p></td><td><p dir="ltr"><strong>2 (8.7)</strong></p></td><td><p dir="ltr"><strong>32 (55.2)</strong></p></td><td><p dir="ltr"><strong>13 (48.1)</strong></p></td><td><p dir="ltr"><strong>40 (72.7)</strong></p></td></tr><tr><td><p dir="ltr"><strong>JIA ACR90 Response</strong></p></td><td><p dir="ltr"><strong>2 (8.7)</strong></p></td><td><p dir="ltr"><strong>17 (29.3)</strong></p></td><td><p dir="ltr"><strong>5 (18.5)</strong></p></td><td><p dir="ltr"><strong>32 (58.2)</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Patients randomized to tocilizumab had fewer ACR30 flares and higher overall ACR responses than patients receiving placebo regardless of a history of prior biologic use.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>CRS</strong></p><p dir="ltr"><strong>The efficacy of Actemra for the treatment of CRS was assessed in a retrospective analysis of data from clinical trials of CAR T-cell therapies (tisagenlecleucel and axicabtagene ciloleucel) for hematological malignancies. Evaluable patients had been treated with tocilizumab 8 mg/kg (12 mg/kg for patients &lt; 30 kg) with or without additional high-dose corticosteroids for severe or life-threatening CRS; only the first episode of CRS was included in the analysis. The efficacy population for the tisagenlecleucel cohort included 28 males and 23 females (total 51 patients) of median age 17 years (range, 3&ndash;68 years). The median time from start of CRS to first dose of tocilizumab was 3 days (range, 0&ndash;18 days). Resolution of CRS was defined as lack of fever and off vasopressors for at least 24 hours. Patients were considered responders if CRS resolved within 14 days of the first dose of tocilizumab, if no more than 2 doses of Actemra were needed, and no drugs other than Actemra and corticosteroids were used for treatment. Thirty-nine patients (76.5%; 95% CI: 62.5%&ndash;87.2%) achieved a response. In an independent cohort of 15 patients (range: 9&ndash;75 years old) with axicabtagene ciloleucel-induced CRS, 53% responded.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The European Medicines Agency has waived the obligation to submit the results of studies with Actemra in all subsets of the paediatric population in treatment of cytokine release syndrome associated with chimeric antigen receptor (CAR) T cell therapy.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>RA Patients</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Intravenous use</strong></p><p dir="ltr"><strong>The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8&nbsp;mg/kg tocilizumab every 4 weeks for 24 weeks or with 162 mg tocilizumab given subcutaneously either once a week or every other week for 24 weeks.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The following parameters (predicted mean &plusmn;&nbsp;SD) were estimated for a dose of 8&nbsp;mg/kg tocilizumab given every 4 weeks: steady-state area under curve (AUC) = 38000&nbsp;&plusmn;&nbsp;13000&nbsp;h &micro;g/mL, trough concentration (Cmin) = 15.9&nbsp;&plusmn;&nbsp;13.1&nbsp;&mu;g/mL and maximum concentration (Cmax) = 182&nbsp;&plusmn;&nbsp;50.4&nbsp;&micro;g/mL, and the accumulation ratios for AUC and Cmax were small, 1.32 and 1.09, respectively. The accumulation ratio was higher for Cmin (2.49), which was expected based on the non-linear clearance contribution at lower concentrations. Steady-state was reached following the first administration for Cmax and after 8 and 20 weeks for AUC and Cmin, respectively. Tocilizumab AUC, Cmin and Cmax increased with increase of body weight. At body weight &ge; 100&nbsp;kg, the predicted mean (&plusmn; SD) steady-state AUC, Cmin and Cmax of tocilizumab were 50000 &plusmn; 16800&nbsp;&mu;g&bull;h/mL, 24.4 &plusmn; 17.5&nbsp;&mu;g/mL, and 226 &plusmn; 50.3&nbsp;&mu;g/mL, respectively, which are higher than mean exposure values for the patient population (i.e. all body weights) reported above. The dose-response curve for tocilizumab flattens at higher exposure, resulting in smaller efficacy gains for each incremental increase in tocilizumab concentration such that clinically meaningful increases in efficacy were not demonstrated in patients treated with &gt; 800&nbsp;mg of tocilizumab. Therefore, tocilizumab doses exceeding 800&nbsp;mg per infusion are not recommended (see section 4.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Distribution</strong></p><p dir="ltr"><strong>In RA patients the central volume of distribution was 3.72, the peripheral volume of distribution was 3.35 resulting in a volume of distribution at steady state of 7.07.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elimination</strong></p><p dir="ltr"><strong>Following intravenous administration, tocilizumab undergoes biphasic elimination from the circulation. The total clearance of tocilizumab was concentration-dependent and is the sum of the linear and non-linear clearance. The linear clearance was estimated as a parameter in the population pharmacokinetic analysis and was 9.5&nbsp;mL/h. The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations. Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The t1/2 of tocilizumab was concentration-dependent. At steady-state following a dose of 8&nbsp;mg/kg every 4 weeks, the effective t1/2 decreased with decreasing concentrations within a dosing interval from 18 days to 6 days.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Linearity</strong></p><p dir="ltr"><strong>Pharmacokinetic parameters of tocilizumab did not change with time. A more than dose-proportional increase in the AUC and Cmin was observed for doses of 4 and 8&nbsp;mg/kg every 4 weeks. Cmax increased dose-proportionally. At steady-state, predicted AUC and Cmin were 3.2 and 30 fold higher at 8&nbsp;mg/kg as compared to 4&nbsp;mg/kg, respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p dir="ltr"><strong>Renal impairment: No formal study of the effect of renal impairment on the pharmacokinetics of tocilizumab has been conducted. Most of the patients in the population pharmacokinetic analysis had normal renal function or mild renal impairment. Mild renal impairment (creatinine clearance based on Cockcroft-Gault &lt;&nbsp;80&nbsp;mL/min and &ge;&nbsp;50&nbsp;mL/min) did not impact the pharmacokinetics of tocilizumab.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic impairment: No formal study of the effect of hepatic impairment on the pharmacokinetics of tocilizumab has been conducted.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Age, gender and ethnicity: Population pharmacokinetic analyses in RA patients, showed that age, gender and ethnic origin did not affect the pharmacokinetics of tocilizumab.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>sJIA Patients:&nbsp;</strong></p><p dir="ltr"><strong>The pharmacokinetics of tocilizumab were determined using a population pharmacokinetic analysis on a database composed of 140 sJIA patients treated with 8&nbsp;mg/kg IV every 2 weeks (patients with a body weight &ge; 30&nbsp;kg ) 12&nbsp;mg/kg IV every 2 weeks (patients with a body weight &lt;&nbsp;30&nbsp;kg), 162&nbsp;mg SC every week (patients weighing &ge; 30 kg), 162 mg SC every 10 days or every 2 weeks (patients weighing below 30 kg).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 10. Predicted mean &plusmn; SD PK parameters at steady-state after IV dosing in sJIA</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Actemra PK Parameter</strong></p></td><td><p dir="ltr"><strong>8 mg/kg Q2W &ge; 30 kg</strong></p></td><td><p dir="ltr"><strong>12 mg/kg Q2W below 30 kg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmax (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>256 &plusmn; 60.8</strong></p></td><td><p dir="ltr"><strong>274 &plusmn;&nbsp;63.8</strong></p></td></tr><tr><td><p dir="ltr"><strong>Ctrough (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>69.7 &plusmn; 29.1</strong></p></td><td><p dir="ltr"><strong>68.4 &plusmn;&nbsp;30.0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmean (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>119 &plusmn; 36.0</strong></p></td><td><p dir="ltr"><strong>123 &plusmn;&nbsp; 36.0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Accumulation Cmax</strong></p></td><td><p dir="ltr"><strong>1.42</strong></p></td><td><p dir="ltr"><strong>1.37</strong></p></td></tr><tr><td><p dir="ltr"><strong>Accumulation Ctrough</strong></p></td><td><p dir="ltr"><strong>3.20</strong></p></td><td><p dir="ltr"><strong>3.41</strong></p></td></tr><tr><td><p dir="ltr"><strong>Accumulation Cmean or AUC&tau;*</strong></p></td><td><p dir="ltr"><strong>2.01</strong></p></td><td><p dir="ltr"><strong>1.95</strong></p></td></tr></tbody></table><p dir="ltr"><strong>*&tau; = 2 weeks for IV regimens&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>After IV dosing, approximately 90% of the steady-state was reached by week 8 for both the 12&nbsp;mg/kg (BW &lt;&nbsp;30&nbsp;kg) and 8&nbsp;mg/kg Q2W (BW &ge;&nbsp;30&nbsp;kg) regimens.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In sJIA patients, the central volume of distribution was 1.87&nbsp;L and the peripheral volume of distribution was 2.14&nbsp;L resulting in a volume of distribution at a steady state of 4.01&nbsp;L. The linear clearance estimated as a parameter in the population pharmacokinetic analysis, was 5.7&nbsp;mL/h.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The half life of tocilizumab in sJIA patients is up to 16 days for the two body weight categories (8&nbsp;mg/kg for body weight &ge;&nbsp;30&nbsp;kg or 12&nbsp;mg/kg for body weight &lt;&nbsp;30&nbsp;kg) at week 12.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>pJIA Patients:&nbsp;</strong></p><p dir="ltr"><strong>The pharmacokinetics of tocilizumab in pJIA patients was characterized by a population pharmacokinetic analysis which included 237 patients who were treated with 8 mg/kg IV every 4 weeks (patients weighing &ge; 30 kg ), 10 mg/kg IV every 4 weeks (patients weighing below 30 kg), 162 mg SC every 2 weeks (patients weighing &ge; 30 kg), or 162 mg SC every 3 weeks (patients weighing below 30 kg).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 11. Predicted mean &plusmn; SD PK parameters at steady-state after IV dosing in pJIA</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Actemra PK Parameter</strong></p></td><td><p dir="ltr"><strong>8 mg/kg Q4W &ge; 30 kg</strong></p></td><td><p dir="ltr"><strong>10 mg/kg Q4W below 30 kg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmax (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>183 &plusmn; 42.3</strong></p></td><td><p dir="ltr"><strong>168 &plusmn;&nbsp;24.8</strong></p></td></tr><tr><td><p dir="ltr"><strong>Ctrough (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>6.55 &plusmn; 7.93</strong></p></td><td><p dir="ltr"><strong>1.47 &plusmn;&nbsp;2.44</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmean (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>42.2 &plusmn; 13.4</strong></p></td><td><p dir="ltr"><strong>31.6 &plusmn;&nbsp; 7.84</strong></p></td></tr><tr><td><p dir="ltr"><strong>Accumulation Cmax</strong></p></td><td><p dir="ltr"><strong>1.04</strong></p></td><td><p dir="ltr"><strong>1.01</strong></p></td></tr><tr><td><p dir="ltr"><strong>Accumulation Ctrough</strong></p></td><td><p dir="ltr"><strong>2.22</strong></p></td><td><p dir="ltr"><strong>1.43</strong></p></td></tr><tr><td><p dir="ltr"><strong>Accumulation Cmean or AUC&tau;*</strong></p></td><td><p dir="ltr"><strong>1.16</strong></p></td><td><p dir="ltr"><strong>1.05</strong></p></td></tr></tbody></table><p dir="ltr"><strong>*&tau; = 4 weeks for IV regimens&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>After IV dosing, approximately 90% of the steady-state was reached by week 12 for the 10&nbsp;mg/kg (BW &lt;&nbsp;30 kg), and by week 16 for the 8&nbsp;mg/kg (BW &ge;&nbsp;30&nbsp;kg) dose.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The half life of tocilizumab in pJIA patients is up to 16 days for the two body weight categories (8&nbsp;mg/kg for body weight &ge; 30 kg or 10 mg/kg for body weight &lt; 30 kg) during a dosing interval at steady state.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Carcinogenicity studies were not performed because IgG1 monoclonal antibodies are not deemed to have intrinsic carcinogenic potential.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Available non-clinical data demonstrated the effect of IL-6 on malignant progression and apoptosis resistance to various cancer types. This data does not suggest a relevant risk for cancer initiation and progression under tocilizumab treatment. Additionally, proliferative lesions were not observed in a 6-month chronic toxicity study in cynomolgus monkeys or in IL-6 deficient mice.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Available non-clinical data do not suggest an effect on fertility under tocilizumab treatment. Effects on endocrine active and reproductive system organs were not observed in a chronic cynomolgus monkey toxicity study and reproductive performance was not affected in IL-6 deficient mice. Tocilizumab administered to cynomolgus monkeys during early gestation, was observed to have no direct or indirect harmful effect on pregnancy or embryonal-foetal development. However, a slight increase in abortion/embryonal-foetal death was observed with high systemic exposure (&gt;&nbsp;100 x human exposure) in the 50&nbsp;mg/kg/day high-dose group compared to placebo and other low-dose groups. Although IL-6 does not seem to be a critical cytokine for foetal growth or the immunological control of the maternal/foetal interface, a relation of this finding to tocilizumab cannot be excluded.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Treatment with a murine analogue did not exert toxicity in juvenile mice. In particular, there was no impairment of skeletal growth, immune function and sexual maturation.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Sucrose</strong></p><p dir="ltr"><strong>Polysorbate 80</strong></p><p dir="ltr"><strong>Disodium phosphate dodecahydrate</strong></p><p dir="ltr"><strong>Sodium dihydrogen phosphate dihydrate</strong></p><p dir="ltr"><strong>Water for injections</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial: 30 months

Diluted product: After dilution, the prepared solution for infusion is physically and chemically stable in sodium chloride 9 mg/mL (0.9%) solution for injection at 30ºC for 24 hours. 

From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C–8°C, unless dilution has taken place in controlled and validated aseptic conditions. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Store vials in a refrigerator (2&deg;C&ndash;8&deg;C). Do not freeze.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Keep the vial(s) in the outer carton in order to protect from light.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For storage conditions of the diluted medicinal product see section 6.3.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Actemra is supplied in a vial (type I glass) with a stopper (butyl rubber) containing 4&nbsp;mL, 10&nbsp;mL or 20&nbsp;mL concentrate. Pack sizes of 1 and 4 vials.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Not all pack sizes may be marketed.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Instructions for dilution prior to administration</strong></p><p dir="ltr"><strong>Parenteral medicinal products should be inspected visually for particulate matter or discolouration prior to administration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be diluted.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>RA and CRS Patients (&ge; 30&nbsp;kg)</strong></p><p dir="ltr"><strong>Withdraw a volume of sterile, non-pyrogenic sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection from a 100&nbsp;mL infusion bag, equal to the volume of Actemra concentrate required for the patients dose, under aseptic conditions. The required amount of Actemra concentrate (0.4&nbsp;mL/kg) should be withdrawn from the vial and placed in the 100&nbsp;mL infusion bag. This should be a final volume of 100&nbsp;mL. To mix the solution, gently invert the infusion bag to avoid foaming.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Use in the paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>sJIA, pJIA and CRS Patients &ge; 30&nbsp;kg</strong></p><p dir="ltr"><strong>Withdraw a volume of sterile, non-pyrogenic sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection from a 100&nbsp;mL infusion bag, equal to the volume of Actemra concentrate required for the patients dose, under aseptic conditions. The required amount of Actemra concentrate (0.4&nbsp;mL/kg) should be withdrawn from the vial and placed in the 100&nbsp;mL infusion bag. This should be a final volume of 100&nbsp;mL. To mix the solution, gently invert the infusion bag to avoid foaming.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>sJIA and CRS Patients &lt;&nbsp;30&nbsp;kg</strong></p><p dir="ltr"><strong>Withdraw a volume of sterile, non-pyrogenic sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection from a 50&nbsp;mL infusion bag, equal to the volume of Actemra concentrate required for the patients dose, under aseptic conditions. The required amount of Actemra concentrate (0.6&nbsp;mL/kg) should be withdrawn from the vial and placed in the 50&nbsp;mL infusion bag. This should be a final volume of 50&nbsp;mL. To mix the solution, gently invert the infusion bag to avoid foaming.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>pJIA Patients &lt;&nbsp;30 kg</strong></p><p dir="ltr"><strong>Withdraw a volume of sterile, non-pyrogenic sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection from a 50&nbsp;mL infusion bag, equal to the volume of Actemra concentrate required for the patients dose, under aseptic conditions. The required amount of Actemra concentrate (0.5&nbsp;mL/kg) should be withdrawn from the vial and placed in the 50&nbsp;mL infusion bag. This should be a final volume of 50&nbsp;mL. To mix the solution, gently invert the infusion bag to avoid foaming.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Actemra is for single-use only.</strong></p><p dir="ltr"><strong>Any unused product or waste material should be disposed of in accordance with local requirements.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124,
CH-4070 Basel,
Switzerland.

8.	MARKETING AUTHORISATION NUMBER(S) 

271-24-14
272-24-14
273-24-14

9.	DATE OF FIRST AUTHORISATION/DATE OF LATEST RENEWAL 

Date of first authorisation: 05 May 2014.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                15 January 2019

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>